



## Clinical trial results:

### A Multicenter, Randomized, Addition to Baseline Treatment, Double-Blind, Placebo-Controlled, Phase III Study to Evaluate the Efficacy and Safety of Satralizumab (SA237) in Patients with Neuromyelitis Optica (NMO) and NMO Spectrum Disorder (NMOSD)

#### Summary

EudraCT number	2013-003752-21
Trial protocol	GB DE IT PL HU ES
Global end of trial date	

#### Results information

Result version number	v1
This version publication date	27 September 2020
First version publication date	27 September 2020

#### Trial information

##### Trial identification

Sponsor protocol code	BN40898
-----------------------	---------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT02028884
WHO universal trial number (UTN)	-

Notes:

#### Sponsors

Sponsor organisation name	F. Hoffmann-La Roche AG
Sponsor organisation address	Grenzacherstrasse 124, Basel, Switzerland, CH-4070
Public contact	F. Hoffmann-La Roche AG, F. Hoffmann-La Roche AG, 41 616878333, global.trial_information@roche.com
Scientific contact	F. Hoffmann-La Roche AG, F. Hoffmann-La Roche AG, 41 616878333, global.trial_information@roche.com

Notes:

#### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	Yes
EMA paediatric investigation plan number(s)	EMA-001625-PIP01-14
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Interim
Date of interim/final analysis	06 June 2018
Is this the analysis of the primary completion data?	Yes
Primary completion date	06 June 2018
Global end of trial reached?	No

Notes:

## General information about the trial

Main objective of the trial:

The main objective of this study was to evaluate the efficacy of satralizumab, compared with placebo, in addition to baseline immunosuppressive treatment in participants with neuromyelitis optica (NMO) and NMO spectrum disorder (NMOSD).

Protection of trial subjects:

All study subjects were required to read and sign an Informed Consent Form.

Background therapy:

All participants received corticosteroids as background therapy.

Evidence for comparator: -

Actual start date of recruitment	20 February 2014
Long term follow-up planned	Yes
Long term follow-up rationale	Safety
Long term follow-up duration	1 Years
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Australia: 3
Country: Number of subjects enrolled	Germany: 4
Country: Number of subjects enrolled	France: 1
Country: Number of subjects enrolled	United Kingdom: 2
Country: Number of subjects enrolled	Hungary: 2
Country: Number of subjects enrolled	Italy: 9
Country: Number of subjects enrolled	Japan: 22
Country: Number of subjects enrolled	Poland: 23
Country: Number of subjects enrolled	Taiwan: 12
Country: Number of subjects enrolled	Ukraine: 3
Country: Number of subjects enrolled	United States: 2
Worldwide total number of subjects	83
EEA total number of subjects	41

Notes:

### Subjects enrolled per age group

In utero	0
----------	---

Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	7
Adults (18-64 years)	72
From 65 to 84 years	4
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details:

Participants took part in the double-blind period up to the clinical cut-off date (CCOD: 06 June 2018). The CCOD was defined by the onset date of the 26th clinical endpoint committee-confirmed protocol-defined relapse (PDR). The study is ongoing in the open label extension period.

### Pre-assignment

Screening details:

Participants with neuromyelitis optica (NMO) or NMO spectrum disorder (NMOSD) were randomized 1:1 to receive either satralizumab 120 mg or matching placebo, in addition to baseline immunosuppressive treatments.

### Period 1

Period 1 title	Double-blind Period
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Monitor, Data analyst, Carer, Assessor

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Placebo + Baseline Treatment, then Satralizumab

Arm description:

Participants received matching placebo, subcutaneous (SC) at Weeks 0, 2 and 4, and every 4 weeks (Q4W) thereafter throughout the double-blind (DB) period up to protocol-defined relapse or treated relapse in addition to baseline treatment. Following the DB period all participants received satralizumab 120 mg SC injection (with or without baseline treatment) at Weeks 0, 2 and 4, and Q4W thereafter up to the clinical cut-off date (CCOD). At the CCOD, participants who had not experienced a relapse during the DB period were invited to initiate satralizumab 120 mg SC injection (with or without baseline treatment at Weeks 0, 2 and 4, and Q4W thereafter) after 4 weeks from their last study treatment dose in the DB period.

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Placebo was administered subcutaneously (SC) at Weeks 0, 2, and 4, and thereafter once every 4 weeks (Q4W).

Investigational medicinal product name	Baseline treatment
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

One of the following drugs at a stable dose was required as monotherapy for baseline treatment during the double-blind period: azathioprine (AZA); mycophenolate mofetil (MMF); or oral corticosteroids (CS). For participants aged 12 to 17 years at the time of informed consent, baseline treatment with AZA or MMF in combination with oral CS was also permitted. Change or termination of baseline treatment was only permitted during the open-label extension period.

<b>Arm title</b>	Satralizumab + Baseline Treatment, then Satralizumab
------------------	--

Arm description:

Participants received satralizumab 120 mg SC injection at Weeks 0, 2 and 4, and Q4W thereafter

throughout the DB period up to protocol-defined relapse or treated relapse in addition to baseline treatment. Following the DB period all participants received satralizumab 120 mg SC injection (with or without baseline treatment) at Weeks 0, 2 and 4, and Q4W thereafter up to the CCOD. At the CCOD, participants who had not experienced a relapse during the DB period were invited to continue satralizumab 120 mg SC injection (with or without baseline treatment at Weeks 0, 2 and 4, and Q4W thereafter) after 4 weeks from their last study treatment dose in the DB period.

Arm type	Experimental
Investigational medicinal product name	Baseline treatment
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

One of the following drugs at a stable dose was required as monotherapy for baseline treatment during the double-blind period: azathioprine (AZA); mycophenolate mofetil (MMF); or oral corticosteroids (CS). For participants aged 12 to 17 years at the time of informed consent, baseline treatment with AZA or MMF in combination with oral CS was also permitted. Change or termination of baseline treatment was only permitted during the open-label extension period.

Investigational medicinal product name	Satralizumab
Investigational medicinal product code	
Other name	SA237, RG6168, RO5333787
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Satralizumab was administered SC at Weeks 0, 2, and 4, and thereafter once every 4 weeks Q4W.

Number of subjects in period 1	Placebo + Baseline Treatment, then Satralizumab	Satralizumab + Baseline Treatment, then Satralizumab
Started	42	41
Completed	24	18
Not completed	18	23
Consent withdrawn by subject	2	-
Adverse event, non-fatal	5	3
Eligibility Violation	1	-
Non-Compliance With Study Drug	2	-
On-going in Study	8	20

## Period 2

Period 2 title	Open-label Extension Period
Is this the baseline period?	No
Allocation method	Not applicable
Blinding used	Not blinded

## Arms

Are arms mutually exclusive?	Yes
------------------------------	-----

<b>Arm title</b>	Placebo + Baseline Treatment, then Satralizumab
------------------	---

**Arm description:**

Participants received matching placebo, subcutaneous (SC) at Weeks 0, 2 and 4, and every 4 weeks (Q4W) thereafter throughout the double-blind (DB) period up to protocol-defined relapse or treated relapse in addition to baseline treatment. Following the DB period (up to approximately 216 weeks), all participants received satralizumab 120 mg SC injection (with or without baseline treatment) at Weeks 0, 2 and 4, and Q4W thereafter up to the clinical cut-off date (CCOD). At the CCOD, participants who had not experienced a relapse during the DB period were invited to initiate satralizumab 120 mg SC injection (with or without baseline treatment at Weeks 0, 2 and 4, and Q4W thereafter) after 4 weeks from their last study treatment dose in the DB period.

Arm type	Placebo
Investigational medicinal product name	Baseline treatment
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

**Dosage and administration details:**

One of the following drugs at a stable dose was required as monotherapy for baseline treatment during the double-blind period: azathioprine (AZA); mycophenolate mofetil (MMF); or oral corticosteroids (CS). For participants aged 12 to 17 years at the time of informed consent, baseline treatment with AZA or MMF in combination with oral CS was also permitted. Change or termination of baseline treatment was only permitted during the open-label extension period.

Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

**Dosage and administration details:**

Placebo was administered subcutaneously (SC) at Weeks 0, 2, and 4, and thereafter once every 4 weeks (Q4W).

<b>Arm title</b>	Satralizumab + Baseline Treatment, then Satralizumab
------------------	--

**Arm description:**

Participants received satralizumab 120 mg SC injection at Weeks 0, 2 and 4, and Q4W thereafter throughout the DB period up to protocol-defined relapse or treated relapse in addition to baseline treatment. Following the DB period (up to approximately 216 weeks), all participants received satralizumab 120 mg SC injection (with or without baseline treatment) at Weeks 0, 2 and 4, and Q4W thereafter up to the CCOD. At the CCOD, participants who had not experienced a relapse during the DB period were invited to continue satralizumab 120 mg SC injection (with or without baseline treatment at Weeks 0, 2 and 4, and Q4W thereafter) after 4 weeks from their last study treatment dose in the DB period.

Arm type	Experimental
Investigational medicinal product name	Baseline treatment
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

**Dosage and administration details:**

One of the following drugs at a stable dose was required as monotherapy for baseline treatment during the double-blind period: azathioprine (AZA); mycophenolate mofetil (MMF); or oral corticosteroids (CS). For participants aged 12 to 17 years at the time of informed consent, baseline treatment with AZA or MMF in combination with oral CS was also permitted. Change or termination of baseline treatment was only permitted during the open-label extension period.

Investigational medicinal product name	Satralizumab
Investigational medicinal product code	
Other name	SA237, RG6168, RO5333787
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

---

**Dosage and administration details:**

Satralizumab was administered SC at Weeks 0, 2, and 4, and thereafter once every 4 weeks Q4W.

<b>Number of subjects in period 2</b>	Placebo + Baseline Treatment, then Satralizumab	Satralizumab + Baseline Treatment, then Satralizumab
Started	24	18
Completed	0	0
Not completed	24	18
Consent withdrawn by subject	-	2
Adverse event, non-fatal	2	1
On-going in Study	19	14
Non-Compliance With Study Drug	-	1
Lack of efficacy	3	-

## Baseline characteristics

### Reporting groups

Reporting group title	Placebo + Baseline Treatment, then Satralizumab
-----------------------	---

Reporting group description:

Participants received matching placebo, subcutaneous (SC) at Weeks 0, 2 and 4, and every 4 weeks (Q4W) thereafter throughout the double-blind (DB) period up to protocol-defined relapse or treated relapse in addition to baseline treatment. Following the DB period all participants received satralizumab 120 mg SC injection (with or without baseline treatment) at Weeks 0, 2 and 4, and Q4W thereafter up to the clinical cut-off date (CCOD). At the CCOD, participants who had not experienced a relapse during the DB period were invited to initiate satralizumab 120 mg SC injection (with or without baseline treatment at Weeks 0, 2 and 4, and Q4W thereafter) after 4 weeks from their last study treatment dose in the DB period.

Reporting group title	Satralizumab + Baseline Treatment, then Satralizumab
-----------------------	--

Reporting group description:

Participants received satralizumab 120 mg SC injection at Weeks 0, 2 and 4, and Q4W thereafter throughout the DB period up to protocol-defined relapse or treated relapse in addition to baseline treatment. Following the DB period all participants received satralizumab 120 mg SC injection (with or without baseline treatment) at Weeks 0, 2 and 4, and Q4W thereafter up to the CCOD. At the CCOD, participants who had not experienced a relapse during the DB period were invited to continue satralizumab 120 mg SC injection (with or without baseline treatment at Weeks 0, 2 and 4, and Q4W thereafter) after 4 weeks from their last study treatment dose in the DB period.

Reporting group values	Placebo + Baseline Treatment, then Satralizumab	Satralizumab + Baseline Treatment, then Satralizumab	Total
Number of subjects	42	41	83
Age categorical Units: Subjects			

Age Continuous Units: years arithmetic mean standard deviation	43.38 ± 12.03	40.78 ± 16.09	-
Sex: Female, Male Units:			
Male	2	4	6
Female	40	37	77



## End points

### End points reporting groups

Reporting group title	Placebo + Baseline Treatment, then Satralizumab
-----------------------	---

#### Reporting group description:

Participants received matching placebo, subcutaneous (SC) at Weeks 0, 2 and 4, and every 4 weeks (Q4W) thereafter throughout the double-blind (DB) period up to protocol-defined relapse or treated relapse in addition to baseline treatment. Following the DB period all participants received satralizumab 120 mg SC injection (with or without baseline treatment) at Weeks 0, 2 and 4, and Q4W thereafter up to the clinical cut-off date (CCOD). At the CCOD, participants who had not experienced a relapse during the DB period were invited to initiate satralizumab 120 mg SC injection (with or without baseline treatment at Weeks 0, 2 and 4, and Q4W thereafter) after 4 weeks from their last study treatment dose in the DB period.

Reporting group title	Satralizumab + Baseline Treatment, then Satralizumab
-----------------------	--

#### Reporting group description:

Participants received satralizumab 120 mg SC injection at Weeks 0, 2 and 4, and Q4W thereafter throughout the DB period up to protocol-defined relapse or treated relapse in addition to baseline treatment. Following the DB period all participants received satralizumab 120 mg SC injection (with or without baseline treatment) at Weeks 0, 2 and 4, and Q4W thereafter up to the CCOD. At the CCOD, participants who had not experienced a relapse during the DB period were invited to continue satralizumab 120 mg SC injection (with or without baseline treatment at Weeks 0, 2 and 4, and Q4W thereafter) after 4 weeks from their last study treatment dose in the DB period.

Reporting group title	Placebo + Baseline Treatment, then Satralizumab
-----------------------	---

#### Reporting group description:

Participants received matching placebo, subcutaneous (SC) at Weeks 0, 2 and 4, and every 4 weeks (Q4W) thereafter throughout the double-blind (DB) period up to protocol-defined relapse or treated relapse in addition to baseline treatment. Following the DB period (up to approximately 216 weeks), all participants received satralizumab 120 mg SC injection (with or without baseline treatment) at Weeks 0, 2 and 4, and Q4W thereafter up to the clinical cut-off date (CCOD). At the CCOD, participants who had not experienced a relapse during the DB period were invited to initiate satralizumab 120 mg SC injection (with or without baseline treatment at Weeks 0, 2 and 4, and Q4W thereafter) after 4 weeks from their last study treatment dose in the DB period.

Reporting group title	Satralizumab + Baseline Treatment, then Satralizumab
-----------------------	--

#### Reporting group description:

Participants received satralizumab 120 mg SC injection at Weeks 0, 2 and 4, and Q4W thereafter throughout the DB period up to protocol-defined relapse or treated relapse in addition to baseline treatment. Following the DB period (up to approximately 216 weeks), all participants received satralizumab 120 mg SC injection (with or without baseline treatment) at Weeks 0, 2 and 4, and Q4W thereafter up to the CCOD. At the CCOD, participants who had not experienced a relapse during the DB period were invited to continue satralizumab 120 mg SC injection (with or without baseline treatment at Weeks 0, 2 and 4, and Q4W thereafter) after 4 weeks from their last study treatment dose in the DB period.

### Primary: Time to First Protocol-Defined Relapse (TFR) in the Double-Blind Period

End point title	Time to First Protocol-Defined Relapse (TFR) in the Double-Blind Period
-----------------	---

#### End point description:

TFR was defined as time from randomization to first occurrence of relapse in the DB period. Protocol-defined relapse was occurrence of new or worsening neurological symptoms attributable to neurological NMO or NMOSD as adjudicated by an independent clinical endpoint committee (CEC). Symptoms had to persist for >24 hours and not be attributable to confounding clinical factors (e.g., fever, infection, injury, change in mood, adverse reactions to medications). New or worsening neurological symptoms that occurred < 31 days following onset of a protocol-defined relapse were considered part of same relapse (i.e., if 2 relapses had onset days that were 30 days of one another, they were counted only as 1 relapse), and onset date used in analysis was the date of first relapse. ITT population. 99999 and 9999999=lower and upper limit of CI were not reached due to low number of participants with events. 999999=median was not reached due to low number of participants with events.

End point type	Primary
----------------	---------

End point timeframe:

Up to Week 216

End point values	Placebo + Baseline Treatment, then Satralizumab	Satralizumab + Baseline Treatment, then Satralizumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	42	41		
Units: weeks				
median (confidence interval 95%)	120.6 (37.0 to 9999999)	999999 (99999 to 9999999)		

## Statistical analyses

Statistical analysis title	Satralizumab versus Placebo
Statistical analysis description: Stratified by Baseline annualized relapse rate (ARR: 1, > 1) and geographic region (Asia, EU/Other).	
Comparison groups	Placebo + Baseline Treatment, then Satralizumab v Satralizumab + Baseline Treatment, then Satralizumab
Number of subjects included in analysis	83
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0184
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.38
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.16
upper limit	0.88

## Secondary: Change from Baseline at Week 24 in the Visual Analogue Scale (VAS) Score for Pain

End point title	Change from Baseline at Week 24 in the Visual Analogue Scale (VAS) Score for Pain
End point description: The VAS is a subjective measure of pain consisting of a 100 mm line with two endpoints representing 0 = "no pain" and 100 = "pain as bad as it could be". Participants rated their pain by placing a mark on the line corresponding to their current level of pain. The distance along the line from the "no pain" marker was measured with a ruler giving a pain score out of 100. A higher score indicated more pain and lower scores reflected a better health state. A negative change from baseline indicates an improvement. ANCOVA was used for analysis to report the adjusted mean and standard error (SE). ITT population included all participants randomized to the treatment groups. Missing data were imputed by baseline observation carried forward (BOCF) method.	
End point type	Secondary

End point timeframe:

Baseline, Week 24

End point values	Placebo + Baseline Treatment, then Satralizumab	Satralizumab + Baseline Treatment, then Satralizumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	42	41		
Units: score on scale				
arithmetic mean (standard error)				
Baseline	34.619 ( $\pm$ 4.026)	27.561 ( $\pm$ 4.399)		
Change from Baseline to Week 24	-3.505 ( $\pm$ 2.357)	2.871 ( $\pm$ 2.391)		

## Statistical analyses

Statistical analysis title	Satralizumab versus Placebo
Statistical analysis description:	
ANCOVA model: treatment group as fixed effect and baseline measurements, prior therapy, most recent attack (first attack/relapse) as covariates	
Comparison groups	Placebo + Baseline Treatment, then Satralizumab v Satralizumab + Baseline Treatment, then Satralizumab
Number of subjects included in analysis	83
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0602
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	6.376
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.28
upper limit	13.033
Variability estimate	Standard error of the mean
Dispersion value	3.344

## Secondary: Change from Baseline at Week 24 in the Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue Score

End point title	Change from Baseline at Week 24 in the Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue Score
-----------------	---

End point description:

The FACIT Fatigue scale is a 13-item questionnaire that assesses self-reported fatigue and its impact upon daily activities and function over the past 7 days. As each of the 13 items of the scale ranges from

0-4, the range of possible scores was computed using FACIT scoring algorithm as 0-52, where 0 is the worst possible score and 52 the best which indicated less fatigue. A positive change from baseline indicates an improvement. ANCOVA was used for analysis to report the adjusted mean and SE. ITT population included all participants randomized to the treatment groups. Missing data were imputed by BOCF method.

End point type	Secondary
End point timeframe:	
Baseline, Week 24	

End point values	Placebo + Baseline Treatment, then Satralizumab	Satralizumab + Baseline Treatment, then Satralizumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	42	41		
Units: score on scale				
arithmetic mean (standard error)				
Baseline	33.857 ( $\pm$ 1.746)	34.732 ( $\pm$ 1.646)		
Change from Baseline to Week 24	2.234 ( $\pm$ 0.943)	0.145 ( $\pm$ 0.963)		

## Statistical analyses

Statistical analysis title	Satralizumab versus Placebo
Statistical analysis description:	
ANCOVA model: treatment group as fixed effect and baseline measurements, prior therapy, most recent attack (first attack/relapse) as covariates	
Comparison groups	Placebo + Baseline Treatment, then Satralizumab v Satralizumab + Baseline Treatment, then Satralizumab
Number of subjects included in analysis	83
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1224
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	-2.089
Confidence interval	
level	95 %
sides	2-sided
lower limit	-4.752
upper limit	0.574
Variability estimate	Standard error of the mean
Dispersion value	1.338

## Secondary: Relapse-Free Rate During the DB Period

End point title	Relapse-Free Rate During the DB Period
End point description:	
Protocol-defined relapse was occurrence of new or worsening neurological symptoms attributable to neurological neuromyelitis optica (NMO) or neuromyelitis optica spectrum disorder (NMOSD). Symptoms had to persist for >24 hours and not be attributable to confounding clinical factors (e.g., fever, infection, injury, change in mood, adverse reactions to medications). New or worsening neurological symptoms that occurred < 31 days following onset of a protocol-defined relapse were considered part of same relapse (i.e., if 2 relapses had onset days that were 30 days of one another, they were counted only as 1 relapse), and onset date used in analysis was the date of first relapse. ITT population included all participants randomized to the treatment groups. 6666=0 participants.	
End point type	Secondary
End point timeframe:	
Up to Week 216	

End point values	Placebo + Baseline Treatment, then Satralizumab	Satralizumab + Baseline Treatment, then Satralizumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	34	37		
Units: percentage				
number (not applicable)				
Week 12 (n=34, 37)	89.86	94.99		
Week 24 (n=30, 29)	84.41	88.86		
Week 36 (n=22, 25)	69.49	88.86		
Week 48 (n=19, 24)	66.02	88.86		
Week 72 (n=16, 22)	58.68	81.46		
Week 96 (n=16, 20)	58.68	77.58		
Week 120 (n=12, 19)	54.17	73.70		
Week 144 (n=9, 14)	49.24	73.70		
Week 168 (n=4, 9)	43.77	73.70		
Week 192 (n=0, 2)	6666	73.70		
Week 216 (n=0, 1)	6666	73.70		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Annualized Relapse Rate (ARR) During the DB Period

End point title	Annualized Relapse Rate (ARR) During the DB Period
End point description:	
The ARR is calculated as the total number of participants with relapses experienced divided by the patient-years at risk. Protocol-defined relapse was occurrence of new or worsening neurological symptoms attributable to neurological NMO or NMOSD. Symptoms had to persist for >24 hours and not be attributable to confounding clinical factors (e.g., fever, infection, injury, change in mood, adverse reactions to medications). New or worsening neurological symptoms that occurred < 31 days following onset of a protocol-defined relapse were considered part of same relapse (2 relapses with onset days in 30 days of one another was counted as 1 relapse), onset date used in analysis was the date of first relapse. ITT population included all participants randomized to the treatment groups.	
End point type	Secondary

End point timeframe:

Up to Week 216

End point values	Placebo + Baseline Treatment, then Satralizumab	Satralizumab + Baseline Treatment, then Satralizumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	42	41		
Units: patients w relapse/patient-years at risk				
number (confidence interval 95%)	0.32 (0.19 to 0.51)	0.11 (0.05 to 0.21)		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Change from Baseline in Modified Rankin Scale (mRS) Scores at 24 Week Intervals During the DB Period

End point title	Change from Baseline in Modified Rankin Scale (mRS) Scores at 24 Week Intervals During the DB Period
-----------------	--

End point description:

The mRS is a 7-point disability scale that assesses the degree of disability in participants with neurological impairment. Possible scores range from 0 (no symptoms at all) up to 6 (death). Higher scores reflect increased disability. A negative change from baseline indicates an improvement. ITT population included all participants randomized to the treatment groups. 9999=SD was not calculable for 1 participant. 6666=0 participants.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline up to Week 216

End point values	Placebo + Baseline Treatment, then Satralizumab	Satralizumab + Baseline Treatment, then Satralizumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	42	41		
Units: score on scale				
arithmetic mean (standard deviation)				
Baseline (n=42, 41)	1.55 (± 0.97)	1.90 (± 1.14)		
Change from Baseline at Week 24 (n=29, 29)	-0.03 (± 0.42)	-0.03 (± 0.50)		
Change from Baseline at Week 48 (n=17, 24)	-0.18 (± 0.53)	-0.13 (± 0.45)		
Change from Baseline at Week 72 (n=15, 23)	0.07 (± 0.70)	0.00 (± 0.52)		

Change from Baseline at Week 96 (n=16, 21)	0.13 (± 0.62)	-0.19 (± 0.51)		
Change from Baseline at Week 120 (n=10, 20)	-0.10 (± 0.74)	-0.05 (± 0.51)		
Change from Baseline at Week 144 (n=9, 15)	-0.11 (± 0.93)	-0.20 (± 0.41)		
Change from Baseline at Week 168 (n=3, 9)	-0.67 (± 0.58)	-0.11 (± 0.33)		
Change from Baseline at Week 192 (n=0, 2)	6666 (± 6666)	-0.50 (± 0.71)		
Change from Baseline at Week 216 (n=0, 1)	6666 (± 6666)	0.00 (± 9999)		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change from Baseline in Zarit Burden Interview (ZBI) Scores at 24 Week Intervals During the DB Period

End point title	Change from Baseline in Zarit Burden Interview (ZBI) Scores at 24 Week Intervals During the DB Period
-----------------	---

End point description:

The ZBI is the measurement to assess caregiver burden. The 22 items ask for the strain caregivers perceive. Responses range from 0 (never) to 4 (nearly always). The overall ZBI score ranges from 0 to 88. The higher the total score, the heavier the perceived burden. A negative change from baseline indicates an improvement. ITT population included all participants randomized to the treatment groups. 9999=SD was not calculable for 1 participant.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline up to Week 168

End point values	Placebo + Baseline Treatment, then Satralizumab	Satralizumab + Baseline Treatment, then Satralizumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	16	13		
Units: score on scale				
arithmetic mean (standard deviation)				
Baseline (n=16, 13)	19.31 (± 9.31)	18.92 (± 12.82)		
Change from Baseline at Week 24 (n=9, 7)	-3.44 (± 5.59)	-3.57 (± 7.11)		
Change from Baseline at Week 48 (n=6, 8)	1.17 (± 8.26)	1.13 (± 13.45)		
Change from Baseline at Week 72 (n=5, 7)	2.20 (± 19.64)	-0.71 (± 11.60)		
Change from Baseline at Week 96 (n=5, 6)	3.00 (± 14.98)	4.17 (± 13.33)		
Change from Baseline at Week 120 (n=3, 5)	0.00 (± 3.61)	3.40 (± 9.29)		

Change from Baseline at Week 144 (n=2, 4)	-3.50 (± 12.02)	-3.50 (± 11.33)		
Change from Baseline at Week 168 (n=2, 1)	2.50 (± 13.44)	11.00 (± 9999)		

## Statistical analyses

No statistical analyses for this end point

### Secondary: Change from Baseline in Expanded Disability Status Scale (EDSS) Scores at 24 Week Intervals During the DB Period

End point title	Change from Baseline in Expanded Disability Status Scale (EDSS) Scores at 24 Week Intervals During the DB Period
-----------------	--

End point description:

The EDSS is an ordinal scale with values from 0 points (normal neurological examination) to 10 points (death) increasing in half-point increments once an EDSS of 1.0 has been reached. Higher scores represent increased disability. A negative change from baseline indicates an improvement. ITT population included all participants randomized to the treatment groups. 9999=SD was not calculable for 1 participant. 6666=0 participants.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline up to Week 216

End point values	Placebo + Baseline Treatment, then Satralizumab	Satralizumab + Baseline Treatment, then Satralizumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	41	41		
Units: score on scale				
arithmetic mean (standard deviation)				
Baseline (n=41, 41)	3.63 (± 1.32)	3.83 (± 1.57)		
Change from Baseline at Week 24 (n=29, 29)	-0.21 (± 0.68)	-0.14 (± 0.82)		
Change from Baseline at Week 48 (n=18, 24)	-0.19 (± 0.77)	-0.19 (± 0.67)		
Change from Baseline at Week 72 (n=15, 21)	-0.27 (± 0.68)	-0.29 (± 0.73)		
Change from Baseline at Week 96 (n=16, 21)	-0.19 (± 0.81)	-0.19 (± 0.75)		
Change from Baseline at Week 120 (n=10, 20)	-0.30 (± 0.79)	0.03 (± 0.57)		
Change from Baseline at Week 144 (n=9, 15)	-0.33 (± 0.83)	-0.07 (± 0.62)		
Change from Baseline at Week 168 (n=3, 9)	-0.17 (± 0.76)	-0.06 (± 0.58)		
Change from Baseline at Week 192 (n=0, 2)	6666 (± 6666)	0.00 (± 0.71)		
Change from Baseline at Week 216 (n=0, 1)	6666 (± 6666)	-0.50 (± 9999)		



## Statistical analyses

No statistical analyses for this end point

### Secondary: Change from Baseline in Visual Acuity (Snellen Chart) at 24 Week Intervals During the DB Period

End point title	Change from Baseline in Visual Acuity (Snellen Chart) at 24 Week Intervals During the DB Period
End point description:	
Visual acuity was measured using Snellen 20-foot wall chart and then converted to logMAR visual acuity scoring. Lower values indicate better visual acuity. Data are reported for right eye (OD) and left eye (OS). A negative change from baseline indicates an improvement. ITT population included all participants randomized to the treatment groups. 9999=SD was not calculable for 1 participant. 6666=0 participants.	
End point type	Secondary
End point timeframe:	
Baseline up to Week 216	

End point values	Placebo + Baseline Treatment, then Satralizumab	Satralizumab + Baseline Treatment, then Satralizumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	42	41		
Units: score on scale				
arithmetic mean (standard deviation)				
Baseline: OD (n=42, 41)	0.490 (± 0.928)	0.303 (± 0.593)		
Baseline: OS (n=42, 41)	0.526 (± 0.911)	0.597 (± 1.016)		
Change from Baseline at Week 24: OD (n=30, 29)	-0.064 (± 0.197)	0.042 (± 0.236)		
Change from Baseline at Week 24: OS (n=30, 29)	-0.012 (± 0.107)	0.059 (± 0.319)		
Change from Baseline at Week 48: OD (n=18, 24)	-0.019 (± 0.086)	0.008 (± 0.093)		
Change from Baseline at Week 48: OS (n=18, 24)	0.026 (± 0.096)	0.013 (± 0.061)		
Change from Baseline at Week 72: OD (n=15, 21)	-0.001 (± 0.110)	-0.034 (± 0.111)		
Change from Baseline at Week 72: OS (n=15, 21)	-0.001 (± 0.121)	-0.019 (± 0.077)		
Change from Baseline at Week 96: OD (n=16, 21)	0.018 (± 0.174)	-0.013 (± 0.095)		
Change from Baseline at Week 96: OS (n=16, 21)	-0.078 (± 0.185)	-0.010 (± 0.073)		
Change from Baseline at Week 120: OD (n=10, 20)	0.030 (± 0.150)	0.011 (± 0.103)		

Change from Baseline at Week 120: OS (n=10, 20)	-0.024 (± 0.150)	0.014 (± 0.257)		
Change from Baseline at Week 144: OD (n=9, 15)	0.058 (± 0.231)	-0.016 (± 0.120)		
Change from Baseline at Week 144: OS (n=9, 15)	-0.016 (± 0.165)	-0.028 (± 0.111)		
Change from Baseline at Week 168: OD (n=3, 9)	0.113 (± 0.306)	0.027 (± 0.199)		
Change from Baseline at Week 168: OS (n=3, 9)	0.100 (± 0.173)	-0.024 (± 0.113)		
Change from Baseline at Week 192: OD (n=0, 2)	6666 (± 6666)	0.150 (± 0.099)		
Change from Baseline at Week 192: OS (n=0, 2)	6666 (± 6666)	0.000 (± 0.000)		
Change from Baseline at Week 216: OD (n=0, 1)	6666 (± 6666)	0.120 (± 9999)		
Change from Baseline at Week 216: OS (n=0, 1)	6666 (± 6666)	0.000 (± 9999)		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change from Baseline in Short Form Generic Health Survey (SF-36) Mental Component Summary Scores at 24 Week Intervals During the DB Period

End point title	Change from Baseline in Short Form Generic Health Survey (SF-36) Mental Component Summary Scores at 24 Week Intervals During the DB Period
-----------------	--

End point description:

The SF-36v2 is a multi-purpose, short form health survey with 36 questions. It has 8 domains (vitality, physical functioning, bodily pain, general health, role-physical, role emotional, social role functioning and mental health) of functional health and well-being scores as well as psychometrically based physical and mental health summary measures and a preference-based health utility index. The component scores were transformed to a 0-100 scale, where higher score indicates better quality of life. A positive change from baseline indicates an improvement. ITT population included all participants randomized to the treatment groups. 9999=SD was not calculable for 1 participant. 6666=0 participants.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline up to Week 216

End point values	Placebo + Baseline Treatment, then Satralizumab	Satralizumab + Baseline Treatment, then Satralizumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	42	41		
Units: score on scale				
arithmetic mean (standard deviation)				
Baseline (n=42, 41)	44.77 (± 11.08)	44.56 (± 9.75)		
Change from Baseline at Week 24 (n=28, 29)	2.53 (± 7.58)	0.57 (± 8.99)		

Change from Baseline at Week 48 (n=18, 24)	2.78 (± 7.51)	-0.61 (± 10.97)		
Change from Baseline at Week 72 (n=15, 23)	3.47 (± 7.13)	2.78 (± 8.13)		
Change from Baseline at Week 96 (n=16, 21)	5.16 (± 10.52)	1.06 (± 7.63)		
Change from Baseline at Week 120 (n=10, 20)	3.63 (± 8.62)	0.71 (± 7.23)		
Change from Baseline at Week 144 (n=9, 15)	2.83 (± 8.79)	3.82 (± 7.15)		
Change from Baseline at Week 168 (n=3, 9)	2.79 (± 6.85)	3.60 (± 9.50)		
Change from Baseline at Week 192 (n=0, 2)	6666 (± 6666)	11.60 (± 7.32)		
Change from Baseline at Week 216 (n=0, 1)	6666 (± 6666)	14.05 (± 9999)		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change from Baseline in SF-36 Physical Component Summary Scores at 24 Week Intervals During the DB Period

End point title	Change from Baseline in SF-36 Physical Component Summary Scores at 24 Week Intervals During the DB Period
-----------------	---

End point description:

The SF-36v2 is a multi-purpose, short form health survey with 36 questions. It has 8 domains (vitality, physical functioning, bodily pain, general health, role-physical, role emotional, social role functioning and mental health) of functional health and well-being scores as well as psychometrically based physical and mental health summary measures and a preference-based health utility index. The component scores were transformed to a 0-100 scale, where higher score indicates better quality of life. A positive change from baseline indicates an improvement. ITT population included all participants randomized to the treatment groups. 9999=SD was not calculable for 1 participant. 6666=0 participants.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline up to Week 216

End point values	Placebo + Baseline Treatment, then Satralizumab	Satralizumab + Baseline Treatment, then Satralizumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	42	41		
Units: score on scale				
arithmetic mean (standard deviation)				
Baseline (n=42, 41)	41.54 (± 9.11)	43.60 (± 10.47)		
Change from Baseline at Week 24 (n=28, 29)	2.79 (± 5.61)	1.30 (± 6.01)		
Change from Baseline at Week 48 (n=18, 24)	0.18 (± 5.33)	1.22 (± 5.77)		
Change from Baseline at Week 72 (n=15, 23)	1.97 (± 6.23)	1.16 (± 4.79)		

Change from Baseline at Week 96 (n=16, 21)	-1.15 (± 7.52)	1.88 (± 5.72)		
Change from Baseline at Week 120 (n=10, 20)	-0.13 (± 7.10)	2.34 (± 6.60)		
Change from Baseline at Week 144 (n=9, 15)	1.78 (± 5.50)	3.05 (± 4.23)		
Change from Baseline at Week 168 (n=3, 9)	0.22 (± 9.23)	0.76 (± 5.98)		
Change from Baseline at Week 192 (n=0, 2)	6666 (± 6666)	0.23 (± 0.55)		
Change from Baseline at Week 216 (n=0, 1)	6666 (± 6666)	-1.63 (± 9999)		

## Statistical analyses

No statistical analyses for this end point

### Secondary: Change from Baseline in SF-36 Bodily Pain Domain Scores at 24 Week Intervals During the DB Period

End point title	Change from Baseline in SF-36 Bodily Pain Domain Scores at 24 Week Intervals During the DB Period
-----------------	---

End point description:

The SF-36v2 is a multi-purpose, short form health survey with 36 questions. It has 8 domains (vitality, physical functioning, bodily pain, general health, role-physical, role emotional, social role functioning and mental health) of functional health and well-being scores as well as psychometrically based physical and mental health component summary measures and a preference-based health utility index. The domain scores were transformed to a 0-100 scale, where higher scores indicate better quality of life. A positive change from baseline indicates an improvement. ITT population included all participants randomized to the treatment groups. 9999=SD was not calculable for 1 participant. 6666=0 participants.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline up to Week 216

End point values	Placebo + Baseline Treatment, then Satralizumab	Satralizumab + Baseline Treatment, then Satralizumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	42	41		
Units: score on scale				
arithmetic mean (standard deviation)				
Baseline (n=42, 41)	43.91 (± 10.22)	45.94 (± 11.56)		
Change from Baseline at Week 24 (n=29, 29)	2.71 (± 7.06)	0.03 (± 11.06)		
Change from Baseline at Week 48 (n=18, 24)	0.81 (± 5.60)	0.12 (± 6.99)		
Change from Baseline at Week 72 (n=15, 23)	3.55 (± 8.20)	2.30 (± 6.99)		
Change from Baseline at Week 96 (n=16, 21)	1.31 (± 7.13)	1.15 (± 8.86)		

Change from Baseline at Week 120 (n=10, 20)	2.22 (± 9.96)	-1.45 (± 9.13)		
Change from Baseline at Week 144 (n=9, 15)	3.58 (± 8.53)	3.14 (± 8.18)		
Change from Baseline at Week 168 (n=3, 9)	1.61 (± 10.58)	3.05 (± 9.00)		
Change from Baseline at Week 192 (n=0, 2)	6666 (± 6666)	8.07 (± 0.57)		
Change from Baseline at Week 216 (n=0, 1)	6666 (± 6666)	3.63 (± 9999)		

## Statistical analyses

No statistical analyses for this end point

### Secondary: Change from Baseline in SF-36 General Health Domain Scores at 24 Week Intervals During the DB Period

End point title	Change from Baseline in SF-36 General Health Domain Scores at 24 Week Intervals During the DB Period
-----------------	--

End point description:

The SF-36v2 is a multi-purpose, short form health survey with 36 questions. It has 8 domains (vitality, physical functioning, bodily pain, general health, role-physical, role emotional, social role functioning and mental health) of functional health and well-being scores as well as psychometrically based physical and mental health component summary measures and a preference-based health utility index. The domain scores were transformed to a 0-100 scale, where higher scores indicate better quality of life. A positive change from baseline indicates an improvement. ITT population included all participants randomized to the treatment groups. 9999=SD was not calculable for 1 participant. 6666=0 participants.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline up to Week 216

End point values	Placebo + Baseline Treatment, then Satralizumab	Satralizumab + Baseline Treatment, then Satralizumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	42	41		
Units: score on scale				
arithmetic mean (standard deviation)				
Baseline (n=42, 41)	39.65 (± 7.90)	41.23 (± 9.29)		
Change from Baseline at Week 24 (n=29, 29)	1.84 (± 5.68)	-0.60 (± 7.26)		
Change from Baseline at Week 48 (n=18, 24)	-0.66 (± 5.53)	-0.27 (± 6.00)		
Change from Baseline at Week 72 (n=15, 23)	-0.16 (± 6.25)	0.94 (± 5.57)		
Change from Baseline at Week 96 (n=16, 21)	-1.90 (± 6.17)	1.86 (± 6.12)		
Change from Baseline at Week 120 (n=10, 20)	-0.33 (± 4.03)	3.76 (± 6.72)		

Change from Baseline at Week 144 (n=9, 15)	-0.95 (± 5.66)	5.20 (± 7.11)		
Change from Baseline at Week 168 (n=3, 9)	-5.23 (± 7.41)	3.06 (± 6.99)		
Change from Baseline at Week 192 (n=0, 2)	6666 (± 6666)	1.19 (± 5.04)		
Change from Baseline at Week 216 (n=0, 1)	6666 (± 6666)	-2.38 (± 9999)		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change from Baseline in SF-36 Mental Health Domain Scores at 24 Week Intervals During the DB Period

End point title	Change from Baseline in SF-36 Mental Health Domain Scores at 24 Week Intervals During the DB Period
-----------------	---

End point description:

The SF-36v2 is a multi-purpose, short form health survey with 36 questions. It has 8 domains (vitality, physical functioning, bodily pain, general health, role-physical, role emotional, social role functioning and mental health) of functional health and well-being scores as well as psychometrically based physical and mental health component summary measures and a preference-based health utility index. The domain scores were transformed to a 0-100 scale, where higher scores indicate better quality of life. A positive change from baseline indicates an improvement. ITT population included all participants randomized to the treatment groups. 9999=SD was not calculable for 1 participant. 6666=0 participants.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline up to Week 216

End point values	Placebo + Baseline Treatment, then Satralizumab	Satralizumab + Baseline Treatment, then Satralizumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	42	41		
Units: score on scale				
arithmetic mean (standard deviation)				
Baseline (n=42, 41)	43.71 (± 10.92)	43.59 (± 10.55)		
Change from Baseline at Week 24 (n=29, 29)	5.23 (± 7.69)	0.99 (± 10.21)		
Change from Baseline at Week 48 (n=18, 24)	2.76 (± 8.54)	0.11 (± 10.73)		
Change from Baseline at Week 72 (n=15, 23)	5.23 (± 7.66)	3.18 (± 9.72)		
Change from Baseline at Week 96 (n=16, 21)	4.09 (± 8.49)	2.12 (± 8.13)		
Change from Baseline at Week 120 (n=10, 20)	3.14 (± 7.06)	1.57 (± 6.76)		
Change from Baseline at Week 144 (n=9, 15)	3.49 (± 7.04)	4.88 (± 8.38)		

Change from Baseline at Week 168 (n=3, 9)	4.36 (± 3.02)	4.07 (± 10.72)		
Change from Baseline at Week 192 (n=0, 2)	6666 (± 6666)	13.09 (± 14.80)		
Change from Baseline at Week 216 (n=0, 1)	6666 (± 6666)	23.55 (± 9999)		

## Statistical analyses

No statistical analyses for this end point

### Secondary: Change from Baseline in SF-36 Physical Functioning Domain Scores at 24 Week Intervals During the DB Period

End point title	Change from Baseline in SF-36 Physical Functioning Domain Scores at 24 Week Intervals During the DB Period
-----------------	--

End point description:

The SF-36v2 is a multi-purpose, short form health survey with 36 questions. It has 8 domains (vitality, physical functioning, bodily pain, general health, role-physical, role emotional, social role functioning and mental health) of functional health and well-being scores as well as psychometrically based physical and mental health component summary measures and a preference-based health utility index. The domain scores were transformed to a 0-100 scale, where higher scores indicate better quality of life. A positive change from baseline indicates an improvement. ITT population included all participants randomized to the treatment groups. 9999=SD was not calculable for 1 participant. 6666=0 participants.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline up to Week 216

End point values	Placebo + Baseline Treatment, then Satralizumab	Satralizumab + Baseline Treatment, then Satralizumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	42	41		
Units: score on scale				
arithmetic mean (standard deviation)				
Baseline (n=42, 41)	42.50 (± 10.53)	43.46 (± 10.34)		
Change from Baseline at Week 24 (n=29, 29)	3.56 (± 7.04)	1.49 (± 7.05)		
Change from Baseline at Week 48 (n=18, 24)	1.92 (± 4.30)	1.86 (± 7.73)		
Change from Baseline at Week 72 (n=15, 23)	3.19 (± 6.54)	0.88 (± 6.52)		
Change from Baseline at Week 96 (n=16, 21)	0.84 (± 6.77)	2.37 (± 7.75)		
Change from Baseline at Week 120 (n=10, 20)	-0.19 (± 8.39)	2.58 (± 6.03)		
Change from Baseline at Week 144 (n=9, 15)	2.55 (± 4.06)	3.32 (± 5.72)		
Change from Baseline at Week 168 (n=3, 9)	1.92 (± 5.06)	0.00 (± 5.50)		

Change from Baseline at Week 192 (n=0, 2)	6666 (± 6666)	1.91 (± 2.70)		
Change from Baseline at Week 216 (n=0, 1)	6666 (± 6666)	1.91 (± 9999)		

## Statistical analyses

No statistical analyses for this end point

### Secondary: Change from Baseline in SF-36 Role-Emotional Domain Scores at 24 Week Intervals During the DB Period

End point title	Change from Baseline in SF-36 Role-Emotional Domain Scores at 24 Week Intervals During the DB Period
-----------------	--

End point description:

The SF-36v2 is a multi-purpose, short form health survey with 36 questions. It has 8 domains (vitality, physical functioning, bodily pain, general health, role-physical, role emotional, social role functioning and mental health) of functional health and well-being scores as well as psychometrically based physical and mental health component summary measures and a preference-based health utility index. The domain scores were transformed to a 0-100 scale, where higher scores indicate better quality of life. A positive change from baseline indicates an improvement. ITT population included all participants randomized to the treatment groups. 9999=SD was not calculable for 1 participant. 6666=0 participants.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline up to Week 216

End point values	Placebo + Baseline Treatment, then Satralizumab	Satralizumab + Baseline Treatment, then Satralizumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	42	41		
Units: score on scale				
arithmetic mean (standard deviation)				
Baseline (n=42, 41)	43.98 (± 11.46)	43.01 (± 10.55)		
Change from Baseline at Week 24 (n=28, 29)	2.24 (± 10.35)	0.36 (± 10.12)		
Change from Baseline at Week 48 (n=18, 24)	3.29 (± 8.05)	0.00 (± 12.49)		
Change from Baseline at Week 72 (n=15, 23)	1.39 (± 9.38)	2.57 (± 7.66)		
Change from Baseline at Week 96 (n=16, 21)	4.13 (± 14.40)	0.83 (± 10.20)		
Change from Baseline at Week 120 (n=10, 20)	3.13 (± 12.44)	0.35 (± 6.95)		
Change from Baseline at Week 144 (n=9, 15)	3.09 (± 9.61)	3.25 (± 7.38)		
Change from Baseline at Week 168 (n=3, 9)	1.16 (± 5.32)	4.64 (± 9.05)		
Change from Baseline at Week 192 (n=0, 2)	6666 (± 6666)	12.19 (± 2.46)		



Change from Baseline at Week 216 (n=0, 1)	6666 (± 6666)	6.97 (± 9999)		
--	---------------	---------------	--	--

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change from Baseline in SF-36 Role-Physical Domain Scores at 24 Week Intervals During the DB Period

End point title	Change from Baseline in SF-36 Role-Physical Domain Scores at 24 Week Intervals During the DB Period
-----------------	---

End point description:

The SF-36v2 is a multi-purpose, short form health survey with 36 questions. It has 8 domains (vitality, physical functioning, bodily pain, general health, role-physical, role emotional, social role functioning and mental health) of functional health and well-being scores as well as psychometrically based physical and mental health component summary measures and a preference-based health utility index. The domain scores were transformed to a 0-100 scale, where higher scores indicate better quality of life. A positive change from baseline indicates an improvement. ITT population included all participants randomized to the treatment groups. 9999=SD was not calculable for 1 participant. 6666=0 participants.

End point type	Secondary
End point timeframe:	
Baseline up to Week 216	

End point values	Placebo + Baseline Treatment, then Satralizumab	Satralizumab + Baseline Treatment, then Satralizumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	42	41		
Units: score on scale				
arithmetic mean (standard deviation)				
Baseline (n=42, 41)	40.74 (± 10.12)	41.88 (± 11.38)		
Change from Baseline at Week 24 (n=28, 29)	3.93 (± 9.56)	3.02 (± 6.95)		
Change from Baseline at Week 48 (n=18, 24)	1.37 (± 7.23)	1.40 (± 8.66)		
Change from Baseline at Week 72 (n=15, 23)	2.40 (± 7.94)	2.83 (± 7.81)		
Change from Baseline at Week 96 (n=16, 21)	0.42 (± 9.03)	1.71 (± 4.60)		
Change from Baseline at Week 120 (n=10, 20)	1.57 (± 9.47)	3.14 (± 7.44)		
Change from Baseline at Week 144 (n=9, 15)	2.99 (± 6.05)	2.69 (± 6.80)		
Change from Baseline at Week 168 (n=3, 9)	3.74 (± 10.61)	2.25 (± 6.45)		
Change from Baseline at Week 192 (n=0, 2)	6666 (± 6666)	4.49 (± 6.35)		

Change from Baseline at Week 216 (n=0, 1)	6666 (± 6666)	8.98 (± 9999)		
--	---------------	---------------	--	--

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change from Baseline in SF-36 Social Role Functioning Domain Scores at 24 Week Intervals During the DB Period

End point title	Change from Baseline in SF-36 Social Role Functioning Domain Scores at 24 Week Intervals During the DB Period
-----------------	---

End point description:

The SF-36v2 is a multi-purpose, short form health survey with 36 questions. It has 8 domains (vitality, physical functioning, bodily pain, general health, role-physical, role emotional, social role functioning and mental health) of functional health and well-being scores as well as psychometrically based physical and mental health component summary measures and a preference-based health utility index. The domain scores were transformed to a 0-100 scale, where higher scores indicate better quality of life. A positive change from baseline indicates an improvement. ITT population included all participants randomized to the treatment groups. 9999=SD was not calculable for 1 participant. 6666=0 participants.

End point type	Secondary
End point timeframe:	
Baseline up to Week 216	

End point values	Placebo + Baseline Treatment, then Satralizumab	Satralizumab + Baseline Treatment, then Satralizumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	42	41		
Units: score on scale				
arithmetic mean (standard deviation)				
Baseline (n=42, 41)	41.70 (± 11.62)	44.26 (± 10.92)		
Change from Baseline at Week 24 (n=29, 29)	1.73 (± 7.96)	0.86 (± 8.69)		
Change from Baseline at Week 48 (n=18, 24)	1.12 (± 7.80)	0.00 (± 10.24)		
Change from Baseline at Week 72 (n=15, 23)	2.34 (± 7.78)	2.18 (± 7.22)		
Change from Baseline at Week 96 (n=16, 21)	2.82 (± 11.72)	0.00 (± 9.38)		
Change from Baseline at Week 120 (n=10, 20)	1.51 (± 13.59)	0.25 (± 9.13)		
Change from Baseline at Week 144 (n=9, 15)	0.56 (± 9.85)	2.01 (± 7.29)		
Change from Baseline at Week 168 (n=3, 9)	1.67 (± 22.61)	0.00 (± 5.61)		
Change from Baseline at Week 192 (n=0, 2)	6666 (± 6666)	0.00 (± 0.00)		

Change from Baseline at Week 216 (n=0, 1)	6666 (± 6666)	-5.01 (± 9999)		
--	---------------	----------------	--	--

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change from Baseline in SF-36 Vitality Domain Scores at 24 Week Intervals During the DB Period

End point title	Change from Baseline in SF-36 Vitality Domain Scores at 24 Week Intervals During the DB Period
-----------------	--

End point description:

The SF-36v2 is a multi-purpose, short form health survey with 36 questions. It has 8 domains (vitality, physical functioning, bodily pain, general health, role-physical, role emotional, social role functioning and mental health) of functional health and well-being scores as well as psychometrically based physical and mental health component summary measures and a preference-based health utility index. The domain scores were transformed to a 0-100 scale, where higher scores indicate better quality of life. A positive change from baseline indicates an improvement. ITT population included all participants randomized to the treatment groups. 9999=SD was not calculable for 1 participant. 6666=0 participants.

End point type	Secondary
End point timeframe:	
Baseline up to Week 216	

End point values	Placebo + Baseline Treatment, then Satralizumab	Satralizumab + Baseline Treatment, then Satralizumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	42	41		
Units: score on scale				
arithmetic mean (standard deviation)				
Baseline (n=42, 41)	45.95 (± 9.14)	46.66 (± 9.65)		
Change from Baseline at Week 24 (n=29, 29)	2.66 (± 7.38)	1.74 (± 8.61)		
Change from Baseline at Week 48 (n=18, 24)	1.65 (± 5.60)	-0.25 (± 8.71)		
Change from Baseline at Week 72 (n=15, 23)	4.55 (± 6.91)	1.38 (± 9.12)		
Change from Baseline at Week 96 (n=16, 21)	4.08 (± 8.53)	2.41 (± 8.28)		
Change from Baseline at Week 120 (n=10, 20)	2.97 (± 5.24)	2.67 (± 8.45)		
Change from Baseline at Week 144 (n=9, 15)	3.96 (± 6.12)	4.16 (± 10.03)		
Change from Baseline at Week 168 (n=3, 9)	2.97 (± 2.97)	0.99 (± 10.82)		
Change from Baseline at Week 192 (n=0, 2)	6666 (± 6666)	7.43 (± 10.51)		
Change from Baseline at Week 216 (n=0, 1)	6666 (± 6666)	11.89 (± 9999)		

## Statistical analyses

No statistical analyses for this end point

### Secondary: Change from Baseline in EuroQoL-5 Dimensions (EQ-5D) Index Scores at 24 Week Intervals During the DB Period

End point title	Change from Baseline in EuroQoL-5 Dimensions (EQ-5D) Index Scores at 24 Week Intervals During the DB Period
-----------------	---

End point description:

The EQ-5D is a participant-answered questionnaire measuring 5 dimensions of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression with 3 possible response categories: 1) no problems; 2) some problems; 3) severe problems. The scores from 5 dimensions are used as input to generate EQ-5D index score using scoring algorithm. The EQ-5D index score is scored on a scale of -0.2 to 1. A higher score reflects a better health state. A positive change from baseline indicates an improvement. ITT population included all participants randomized to the treatment groups. 9999=SD was not calculable for 1 participant. 6666=0 participants.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline up to Week 216

End point values	Placebo + Baseline Treatment, then Satralizumab	Satralizumab + Baseline Treatment, then Satralizumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	42	40		
Units: score on scale				
arithmetic mean (standard deviation)				
Baseline (n=42, 40)	0.7297 (± 0.1863)	0.7634 (± 0.1811)		
Change from Baseline at Week 24 (n=29, 28)	0.0649 (± 0.1596)	-0.0082 (± 0.1882)		
Change from Baseline at Week 48 (n=18, 23)	0.0352 (± 0.1830)	0.0011 (± 0.1256)		
Change from Baseline at Week 72 (n=15, 22)	0.0724 (± 0.2088)	0.0241 (± 0.1084)		
Change from Baseline at Week 96 (n=16, 20)	0.0349 (± 0.1758)	0.0167 (± 0.1056)		
Change from Baseline at Week 120 (n=10, 19)	0.0336 (± 0.2111)	0.0257 (± 0.1178)		
Change from Baseline at Week 144 (n=9, 15)	0.0846 (± 0.1650)	0.0488 (± 0.1424)		
Change from Baseline at Week 168 (n=3, 9)	0.0648 (± 0.1031)	0.0307 (± 0.1335)		
Change from Baseline at Week 192 (n=0, 2)	6666 (± 6666)	0.1873 (± 0.2890)		
Change from Baseline at Week 216 (n=0, 1)	6666 (± 6666)	0.3322 (± 9999)		

## Statistical analyses

No statistical analyses for this end point

### Secondary: Serum Satralizumab Concentration During the DB Period

End point title	Serum Satralizumab Concentration During the DB Period <sup>[1]</sup>
-----------------	--

End point description:

The safety analysis population (SAF) included all randomized participants who had received at least 1 dose of satralizumab or placebo. 9999=SD was not calculable for 1 participant.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Weeks 2, 4, 5, 6, 8, and every 4 weeks thereafter up to Week 224

Notes:

[1] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: The endpoint reports data only for the arm treated with satralizumab.

End point values	Satralizumab + Baseline Treatment, then Satralizumab			
Subject group type	Reporting group			
Number of subjects analysed	41			
Units: ng/mL				
arithmetic mean (standard deviation)				
Baseline (n=40)	100.00 (± 0.00)			
Week 2 (n=41)	11343.66 (± 5125.84)			
Week 4 (n=38)	22222.63 (± 8003.48)			
Week 5 (n=20)	28461.00 (± 12542.52)			
Week 6 (n=20)	28174.50 (± 11199.00)			
Week 8 (n=39)	21246.92 (± 9045.31)			
Week 12 (n=38)	20927.63 (± 9536.07)			
Week 16 (n=35)	20274.86 (± 10694.38)			
Week 20 (n=33)	20146.06 (± 10740.65)			
Week 24 (n=30)	20189.00 (± 10140.88)			
Week 28 (n=28)	20826.07 (± 10995.92)			
Week 32 (n=28)	20631.79 (± 11110.94)			

Week 36 (n=26)	21114.62 ( $\pm$ 11190.52)			
Week 40 (n=25)	22224.76 ( $\pm$ 13389.71)			
Week 44 (n=23)	22582.17 ( $\pm$ 12031.13)			
Week 48 (n=25)	23324.80 ( $\pm$ 13979.87)			
Week 52 (n=24)	24570.83 ( $\pm$ 15798.38)			
Week 56 (n=24)	24252.50 ( $\pm$ 15433.80)			
Week 60 (n=24)	23061.67 ( $\pm$ 15777.82)			
Week 64 (n=22)	23369.55 ( $\pm$ 13447.96)			
Week 68 (n=23)	26194.43 ( $\pm$ 16836.77)			
Week 72 (n=23)	26618.87 ( $\pm$ 14999.38)			
Week 76 (n=22)	26539.09 ( $\pm$ 13736.30)			
Week 80 (n=21)	26868.00 ( $\pm$ 14005.87)			
Week 84 (n=21)	27037.62 ( $\pm$ 15460.97)			
Week 88 (n=20)	26203.00 ( $\pm$ 14309.81)			
Week 92 (n=21)	28308.10 ( $\pm$ 15111.34)			
Week 96 (n=21)	26754.43 ( $\pm$ 15146.20)			
Week 100 (n=21)	27707.14 ( $\pm$ 14225.93)			
Week 104 (n=21)	26203.81 ( $\pm$ 13616.28)			
Week 108 (n=21)	26112.38 ( $\pm$ 12521.65)			
Week 112 (n=21)	24925.10 ( $\pm$ 12181.81)			
Week 116 (n=20)	26360.50 ( $\pm$ 13885.76)			
Week 120 (n=20)	24910.00 ( $\pm$ 13217.57)			
Week 124 (n=20)	24689.50 ( $\pm$ 14352.30)			
Week 128 (n=19)	22395.53 ( $\pm$ 12954.00)			
Week 132 (n=19)	23804.74 ( $\pm$ 14878.32)			
Week 136 (n=19)	25856.32 ( $\pm$ 15506.85)			
Week 140 (n=18)	26118.56 ( $\pm$ 15264.89)			
Week 144 (n=15)	27975.33 ( $\pm$ 11536.28)			
Week 148 (n=12)	27935.83 ( $\pm$ 11940.90)			
Week 152 (n=10)	28967.00 ( $\pm$ 10354.22)			
Week 156 (n=9)	27990.00 ( $\pm$ 10444.75)			

Week 160 (n=9)	28983.33 (± 11429.02)			
Week 164 (n=9)	28903.33 (± 10780.69)			
Week 168 (n=9)	23683.33 (± 11615.40)			
Week 172 (n=9)	24498.89 (± 11106.23)			
Week 176 (n=9)	26300.00 (± 11498.48)			
Week 180 (n=6)	28300.00 (± 9431.86)			
Week 184 (n=5)	32380.00 (± 9427.19)			
Week 188 (n=3)	36600.00 (± 8214.62)			
Week 192 (n=2)	32650.00 (± 7848.89)			
Week 196 (n=2)	30800.00 (± 4808.33)			
Week 200 (n=2)	28400.00 (± 3818.38)			
Week 204 (n=2)	25300.00 (± 3252.69)			
Week 208 (n=1)	25900.00 (± 9999)			
Week 212 (n=1)	17000.00 (± 9999)			
Week 216 (n=1)	28600.00 (± 9999)			
Week 220 (n=1)	31600.00 (± 9999)			
Week 224 (n=1)	28700.00 (± 9999)			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Serum Soluble IL-6 Receptor (sIL-6R) Concentration During the DB Period

End point title	Serum Soluble IL-6 Receptor (sIL-6R) Concentration During the DB Period
-----------------	---

End point description:

The SAF included all randomized participants who had received at least 1 dose of satralizumab or placebo. 9999=SD was not calculable for 1 participant. 6666=0 participants.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Weeks 2, 4, and every 4 weeks thereafter up to Week 224

End point values	Placebo + Baseline Treatment, then Satralizumab	Satralizumab + Baseline Treatment, then Satralizumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	42	41		
Units: ng/mL				
arithmetic mean (standard deviation)				
Baseline (n=42, 40)	32.52 (± 7.78)	35.13 (± 21.52)		
Week 2 (n=41, 41)	33.82 (± 8.30)	437.41 (± 72.31)		
Week 4 (n=40, 41)	33.13 (± 8.52)	572.29 (± 94.84)		
Week 8 (n=37, 39)	34.02 (± 9.43)	642.92 (± 115.51)		
Week 12 (n=33, 39)	32.58 (± 8.52)	651.41 (± 99.20)		
Week 16 (n=32, 35)	32.67 (± 9.32)	640.57 (± 97.41)		
Week 20 (n=31, 33)	34.22 (± 8.15)	636.64 (± 109.75)		
Week 24 (n=30, 30)	34.44 (± 9.31)	639.20 (± 108.94)		
Week 28 (n=26, 28)	33.70 (± 8.28)	649.11 (± 131.85)		
Week 32 (n=24, 28)	33.48 (± 8.74)	651.82 (± 162.04)		
Week 36 (n=23, 26)	34.39 (± 11.01)	652.12 (± 124.70)		
Week 40 (n=19, 24)	33.31 (± 7.86)	664.21 (± 158.61)		
Week 44 (n=18, 23)	33.94 (± 7.77)	677.13 (± 173.99)		
Week 48 (n=18, 25)	34.50 (± 9.14)	627.23 (± 217.06)		
Week 52 (n=18, 24)	44.01 (± 44.26)	656.29 (± 173.67)		
Week 56 (n=18, 24)	37.00 (± 7.42)	626.83 (± 155.56)		
Week 60 (n=18, 24)	36.39 (± 7.81)	617.00 (± 142.13)		
Week 64 (n=17, 22)	35.14 (± 8.78)	621.27 (± 152.45)		
Week 68 (n=17, 23)	35.35 (± 8.68)	664.91 (± 130.58)		
Week 72 (n=15, 23)	36.02 (± 10.73)	648.83 (± 134.32)		
Week 76 (n=16, 22)	36.94 (± 9.46)	643.91 (± 118.60)		
Week 80 (n=16, 21)	36.45 (± 9.50)	667.24 (± 133.49)		
Week 84 (n=16, 21)	34.60 (± 8.88)	649.38 (± 137.64)		
Week 88 (n=13, 20)	31.95 (± 8.29)	651.35 (± 150.58)		
Week 92 (n=16, 21)	34.30 (± 9.71)	633.43 (± 134.36)		
Week 96 (n=16, 21)	32.88 (± 9.39)	630.62 (± 162.28)		



Week 100 (n=15, 21)	33.78 (± 9.04)	651.90 (± 162.09)		
Week 104 (n=14, 21)	31.61 (± 9.13)	649.57 (± 185.99)		
Week 108 (n=13, 21)	31.49 (± 9.23)	658.67 (± 152.61)		
Week 112 (n=12, 21)	32.75 (± 7.77)	683.90 (± 135.07)		
Week 116 (n=13, 20)	33.68 (± 8.31)	653.98 (± 194.92)		
Week 120 (n=12, 20)	33.73 (± 6.20)	667.10 (± 152.24)		
Week 124 (n=10, 20)	33.06 (± 9.31)	696.45 (± 138.17)		
Week 128 (n=10, 19)	34.07 (± 8.83)	670.05 (± 138.28)		
Week 132 (n=10, 19)	34.28 (± 4.95)	671.84 (± 138.75)		
Week 136 (n=10, 19)	32.43 (± 8.12)	674.95 (± 170.04)		
Week 140 (n=10, 18)	32.97 (± 6.52)	645.72 (± 132.32)		
Week 144 (n=9, 15)	35.37 (± 8.91)	699.80 (± 101.84)		
Week 148 (n=7, 12)	37.97 (± 12.40)	672.42 (± 107.40)		
Week 152 (n=5, 10)	35.08 (± 9.08)	701.60 (± 110.27)		
Week 156 (n=5, 9)	36.92 (± 7.77)	720.33 (± 103.58)		
Week 160 (n=4, 9)	40.38 (± 7.31)	704.89 (± 109.86)		
Week 164 (n=4, 9)	43.08 (± 10.54)	723.67 (± 136.20)		
Week 168 (n=3, 9)	42.30 (± 5.92)	744.22 (± 123.47)		
Week 172 (n=3, 9)	42.03 (± 5.87)	706.33 (± 127.63)		
Week 176 (n=2, 9)	39.85 (± 6.15)	730.56 (± 121.75)		
Week 180 (n=2, 6)	38.85 (± 12.09)	769.83 (± 119.50)		
Week 184 (n=0, 5)	6666 (± 6666)	736.80 (± 152.09)		
Week 188 (n=0, 3)	6666 (± 6666)	853.67 (± 38.02)		
Week 192 (n=0, 2)	6666 (± 6666)	930.00 (± 49.50)		
Week 196 (n=0, 2)	6666 (± 6666)	887.00 (± 91.92)		
Week 200 (n=0, 2)	6666 (± 6666)	902.50 (± 79.90)		
Week 204 (n=0, 2)	6666 (± 6666)	935.00 (± 7.07)		
Week 208 (n=0, 1)	6666 (± 6666)	941.00 (± 9999)		
Week 212 (n=0, 1)	6666 (± 6666)	971.00 (± 9999)		
Week 216 (n=0, 1)	6666 (± 6666)	896.00 (± 9999)		
Week 220 (n=0, 1)	6666 (± 6666)	901.00 (± 9999)		

Week 224 (n=0, 1)	6666 (± 6666)	831.00 (± 9999)		
-------------------	---------------	-----------------	--	--

## Statistical analyses

No statistical analyses for this end point

## Secondary: Serum High Sensitivity C-Reactive Protein (hsCRP) Concentration During the DB Period

End point title	Serum High Sensitivity C-Reactive Protein (hsCRP) Concentration During the DB Period
-----------------	--

End point description:

The SAF included all randomized participants who had received at least 1 dose of satralizumab or placebo. 9999=SD was not calculable for 1 participant. 6666=0 participants.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Weeks 2, 4, and every 4 weeks thereafter up to Week 224

End point values	Placebo + Baseline Treatment, then Satralizumab	Satralizumab + Baseline Treatment, then Satralizumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	42	41		
Units: mg/L				
arithmetic mean (standard deviation)				
Baseline (n=42, 41)	1.48 (± 2.08)	1.68 (± 2.49)		
Week 2 (n=41, 40)	1.65 (± 2.86)	0.78 (± 2.93)		
Week 4 (n=40, 41)	1.59 (± 2.27)	0.44 (± 0.72)		
Week 8 (n=37, 39)	1.76 (± 2.25)	0.59 (± 1.26)		
Week 12 (n=33, 38)	1.48 (± 2.07)	0.47 (± 0.60)		
Week 16 (n=32, 35)	1.91 (± 3.34)	0.49 (± 0.51)		
Week 20 (n=31, 33)	1.91 (± 3.44)	0.48 (± 0.50)		
Week 24 (n=30, 30)	2.45 (± 6.87)	0.58 (± 0.91)		
Week 28 (n=26, 28)	1.96 (± 3.24)	0.73 (± 1.34)		
Week 32 (n=24, 28)	2.36 (± 4.96)	0.73 (± 1.21)		
Week 36 (n=23, 26)	2.48 (± 3.59)	0.56 (± 0.66)		
Week 40 (n=19, 25)	2.49 (± 4.53)	1.13 (± 2.26)		
Week 44 (n=18, 23)	1.41 (± 1.47)	0.72 (± 1.20)		
Week 48 (n=18, 25)	1.59 (± 2.07)	0.86 (± 1.44)		
Week 52 (n=18, 24)	2.60 (± 3.87)	0.67 (± 0.88)		
Week 56 (n=18, 23)	1.43 (± 1.58)	0.72 (± 1.02)		
Week 60 (n=18, 24)	2.63 (± 4.34)	1.05 (± 2.15)		
Week 64 (n=17, 22)	11.10 (± 40.09)	0.64 (± 0.89)		
Week 68 (n=17, 23)	1.86 (± 2.66)	0.57 (± 0.47)		
Week 72 (n=15, 23)	3.80 (± 8.83)	0.59 (± 0.71)		

Week 76 (n=15, 22)	5.24 (± 10.68)	0.51 (± 0.37)		
Week 80 (n=16, 21)	2.11 (± 2.63)	0.58 (± 0.51)		
Week 84 (n=16, 21)	2.08 (± 2.26)	0.59 (± 0.61)		
Week 88 (n=14, 20)	5.19 (± 12.83)	0.60 (± 0.53)		
Week 92 (n=16, 21)	2.07 (± 2.21)	0.60 (± 0.70)		
Week 96 (n=16, 20)	2.92 (± 4.60)	0.74 (± 1.01)		
Week 100 (n=15, 21)	2.58 (± 4.53)	0.87 (± 1.49)		
Week 104 (n=14, 21)	1.41 (± 2.05)	0.84 (± 1.40)		
Week 108 (n=13, 21)	1.93 (± 2.25)	0.66 (± 0.58)		
Week 112 (n=12, 21)	1.54 (± 1.56)	0.82 (± 0.87)		
Week 116 (n=13, 20)	2.39 (± 3.91)	0.84 (± 1.26)		
Week 120 (n=12, 20)	1.53 (± 1.33)	0.98 (± 1.58)		
Week 124 (n=10, 20)	1.43 (± 1.43)	0.72 (± 0.67)		
Week 128 (n=10, 19)	6.00 (± 16.28)	0.96 (± 1.29)		
Week 132 (n=10, 19)	1.08 (± 0.94)	0.70 (± 0.84)		
Week 136 (n=10, 19)	1.43 (± 1.54)	0.99 (± 1.68)		
Week 140 (n=10, 18)	1.15 (± 1.28)	1.06 (± 2.25)		
Week 144 (n=9, 15)	0.82 (± 0.73)	0.44 (± 0.37)		
Week 148 (n=7, 12)	1.29 (± 1.43)	0.35 (± 0.18)		
Week 152 (n=5, 10)	1.08 (± 0.97)	0.38 (± 0.23)		
Week 156 (n=5, 9)	1.52 (± 1.42)	0.35 (± 0.18)		
Week 160 (n=4, 9)	0.83 (± 0.53)	0.37 (± 0.22)		
Week 164 (n=4, 9)	3.18 (± 4.89)	0.38 (± 0.20)		
Week 168 (n=3, 9)	0.80 (± 0.26)	0.40 (± 0.19)		
Week 172 (n=3, 8)	1.37 (± 1.00)	0.26 (± 0.17)		
Week 176 (n=2, 8)	0.95 (± 0.64)	0.31 (± 0.19)		
Week 180 (n=2, 6)	30.15 (± 41.65)	0.28 (± 0.15)		
Week 184 (n=0, 5)	6666 (± 6666)	0.20 (± 0.11)		
Week 188 (n=0, 3)	6666 (± 6666)	0.37 (± 0.06)		
Week 192 (n=0, 2)	6666 (± 6666)	0.15 (± 0.00)		
Week 196 (n=0, 2)	6666 (± 6666)	0.23 (± 0.11)		
Week 200 (n=0, 2)	6666 (± 6666)	0.23 (± 0.11)		
Week 204 (n=0, 2)	6666 (± 6666)	0.23 (± 0.11)		
Week 208 (n=0, 1)	6666 (± 6666)	0.30 (± 9999)		
Week 212 (n=0, 1)	6666 (± 6666)	0.40 (± 9999)		
Week 216 (n=0, 1)	6666 (± 6666)	0.30 (± 9999)		
Week 220 (n=0, 1)	6666 (± 6666)	0.40 (± 9999)		
Week 224 (n=0, 1)	6666 (± 6666)	0.15 (± 9999)		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Serum Interleukin-6 (IL-6) Concentration During the DB Period

End point title	Serum Interleukin-6 (IL-6) Concentration During the DB Period
-----------------	---

End point description:

The SAF included all randomized participants who had received at least 1 dose of satralizumab or placebo. 9999=SD was not calculable for 1 participant. 6666=0 participants.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Weeks 2, 4, and every 4 weeks thereafter up to Week 224

End point values	Placebo + Baseline Treatment, then Satralizumab	Satralizumab + Baseline Treatment, then Satralizumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	42	41		
Units: pg/mL				
arithmetic mean (standard deviation)				
Baseline (n=42, 40)	1.63 (± 0.39)	1.92 (± 1.36)		
Week 2 (n=41, 41)	1.84 (± 0.95)	40.12 (± 118.83)		
Week 4 (n=40, 41)	2.33 (± 2.99)	28.30 (± 31.31)		
Week 8 (n=37, 38)	1.69 (± 0.55)	32.37 (± 77.99)		
Week 12 (n=33, 39)	1.71 (± 0.60)	22.95 (± 20.55)		
Week 16 (n=32, 35)	1.84 (± 0.90)	25.76 (± 30.85)		
Week 20 (n=31, 33)	2.99 (± 5.45)	23.07 (± 15.37)		
Week 24 (n=30, 29)	2.02 (± 1.52)	21.53 (± 17.91)		
Week 28 (n=26, 28)	1.95 (± 1.38)	25.14 (± 24.27)		
Week 32 (n=24, 28)	1.74 (± 0.84)	23.77 (± 18.53)		
Week 36 (n=23, 26)	2.13 (± 1.41)	23.08 (± 15.56)		
Week 40 (n=19, 24)	1.66 (± 0.40)	27.31 (± 47.45)		
Week 44 (n=17, 21)	1.57 (± 0.00)	17.01 (± 15.38)		
Week 48 (n=18, 25)	1.69 (± 0.53)	19.45 (± 19.36)		
Week 52 (n=18, 24)	2.12 (± 1.36)	21.11 (± 17.42)		
Week 56 (n=18, 22)	1.57 (± 0.00)	21.74 (± 20.96)		
Week 60 (n=18, 23)	2.27 (± 1.46)	23.25 (± 23.36)		
Week 64 (n=17, 22)	2.46 (± 3.22)	24.31 (± 20.74)		
Week 68 (n=17, 23)	1.94 (± 1.14)	31.30 (± 53.79)		
Week 72 (n=15, 23)	1.93 (± 0.97)	24.69 (± 24.45)		
Week 76 (n=16, 21)	2.21 (± 1.87)	20.45 (± 13.79)		
Week 80 (n=16, 21)	2.19 (± 2.51)	23.29 (± 19.64)		
Week 84 (n=16, 21)	2.66 (± 2.36)	22.71 (± 21.49)		

Week 88 (n=12, 20)	2.59 (± 2.77)	29.17 (± 25.58)		
Week 92 (n=16, 20)	1.84 (± 0.77)	24.51 (± 32.02)		
Week 96 (n=16, 21)	3.06 (± 3.19)	21.52 (± 20.20)		
Week 100 (n=15, 21)	2.04 (± 1.02)	21.77 (± 24.98)		
Week 104 (n=13, 21)	1.95 (± 0.96)	22.61 (± 26.55)		
Week 108 (n=13, 21)	1.76 (± 0.70)	24.18 (± 20.55)		
Week 112 (n=12, 21)	1.57 (± 0.00)	32.18 (± 36.15)		
Week 116 (n=13, 20)	1.57 (± 0.00)	22.33 (± 22.20)		
Week 120 (n=12, 20)	1.71 (± 0.52)	21.86 (± 24.54)		
Week 124 (n=9, 19)	1.57 (± 0.00)	26.23 (± 27.67)		
Week 128 (n=10, 19)	1.57 (± 0.00)	25.40 (± 31.20)		
Week 132 (n=10, 19)	1.57 (± 0.00)	25.48 (± 27.38)		
Week 136 (n=10, 19)	1.57 (± 0.00)	27.23 (± 37.56)		
Week 140 (n=10, 18)	1.57 (± 0.00)	20.66 (± 18.10)		
Week 144 (n=9, 15)	1.57 (± 0.00)	16.82 (± 16.16)		
Week 148 (n=7, 12)	2.04 (± 1.25)	17.10 (± 11.33)		
Week 152 (n=5, 10)	1.57 (± 0.00)	16.62 (± 13.75)		
Week 156 (n=5, 8)	2.34 (± 1.72)	12.67 (± 5.73)		
Week 160 (n=4, 9)	1.96 (± 0.80)	11.15 (± 5.12)		
Week 164 (n=4, 9)	1.57 (± 0.00)	12.84 (± 6.93)		
Week 168 (n=3, 9)	1.57 (± 0.00)	13.30 (± 8.89)		
Week 172 (n=3, 9)	1.57 (± 0.00)	13.89 (± 6.94)		
Week 176 (n=2, 9)	1.57 (± 0.00)	15.11 (± 7.16)		
Week 180 (n=2, 6)	1.57 (± 0.00)	13.34 (± 6.68)		
Week 184 (n=0, 5)	6666 (± 6666)	15.24 (± 9.91)		
Week 188 (n=0, 3)	6666 (± 6666)	13.96 (± 9.74)		
Week 192 (n=0, 2)	6666 (± 6666)	16.71 (± 13.15)		
Week 196 (n=0, 2)	6666 (± 6666)	14.34 (± 12.81)		
Week 200 (n=0, 2)	6666 (± 6666)	18.55 (± 8.84)		
Week 204 (n=0, 2)	6666 (± 6666)	18.24 (± 12.53)		
Week 208 (n=0, 1)	6666 (± 6666)	9.95 (± 9999)		
Week 212 (n=0, 1)	6666 (± 6666)	8.02 (± 9999)		
Week 216 (n=0, 1)	6666 (± 6666)	6.45 (± 9999)		
Week 220 (n=0, 1)	6666 (± 6666)	45.80 (± 9999)		
Week 224 (n=0, 1)	6666 (± 6666)	34.30 (± 9999)		

## Statistical analyses

No statistical analyses for this end point

### Secondary: Number of Participants with at Least One Adverse Event in the DB Period

End point title	Number of Participants with at Least One Adverse Event in the DB Period
-----------------	---

End point description:

An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Pre-existing conditions which worsen during a study are also considered as adverse events. The SAF included all randomized participants who had received at least 1 dose of satralizumab or placebo.

End point type	Secondary
----------------	-----------

End point timeframe:

Up to Week 224

End point values	Placebo + Baseline Treatment, then Satralizumab	Satralizumab + Baseline Treatment, then Satralizumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	42	41		
Units: participants	40	37		

## Statistical analyses

No statistical analyses for this end point

### Secondary: Number of Participants with at Least One Serious Adverse Event in the DB Period

End point title	Number of Participants with at Least One Serious Adverse Event in the DB Period
-----------------	---

End point description:

A serious adverse event is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, or is medically significant or requires intervention to prevent one or other of the outcomes listed above. The SAF included all randomized participants who had received at least 1 dose of satralizumab or placebo.

End point type	Secondary
----------------	-----------

End point timeframe:

Up to Week 224

End point values	Placebo + Baseline Treatment, then Satralizumab	Satralizumab + Baseline Treatment, then Satralizumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	42	41		
Units: participants	9	7		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Number of Participants with Non-Serious Adverse Events of Special Interest in the DB Period

End point title	Number of Participants with Non-Serious Adverse Events of Special Interest in the DB Period
End point description: Non-serious adverse events of special interest for this study included: 1) cases of an elevated alanine aminotransferase (ALT) or aspartate aminotransferase (AST) in combination with either an elevated bilirubin or clinical jaundice, 2) suspected transmission of an infectious agent by the study treatment. The SAF included all randomized participants who had received at least 1 dose of satralizumab or placebo.	
End point type	Secondary
End point timeframe: Up to Week 224	

End point values	Placebo + Baseline Treatment, then Satralizumab	Satralizumab + Baseline Treatment, then Satralizumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	42	41		
Units: participants	0	0		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Number of Participants with Selected Adverse Events in the DB Period

End point title	Number of Participants with Selected Adverse Events in the DB Period
End point description: Selected adverse events for this study included: 1) non-serious infections that required treatments with intravenous (IV) antibiotic, antifungal, antiviral, 2) opportunistic infections that required treatments with oral antibiotics, antifungals, or antivirals, 3) injection-related reactions (IRRs; an AE which occurred within 24 hours after study treatment injection except where the event was not considered an allergic reaction), and 4) anaphylaxis (an acute allergic/hypersensitivity reaction). The SAF included all	

randomized participants who had received at least 1 dose of satralizumab or placebo.

End point type	Secondary
End point timeframe:	
Up to Week 224	

End point values	Placebo + Baseline Treatment, then Satralizumab	Satralizumab + Baseline Treatment, then Satralizumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	42	41		
Units: participants				
Non serious Infections requiring IV treatment	4	1		
Potential Opportunistic Infections	5	4		
Injection Related Reactions	2	5		
Anaphylaxis	0	0		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of Participants With Suicidal Behaviors and Ideations Collected by Columbia-Suicide Severity Rating Scale in the DB Period

End point title	Number of Participants With Suicidal Behaviors and Ideations Collected by Columbia-Suicide Severity Rating Scale in the DB Period
-----------------	---

End point description:

The Columbia-Suicide Severity Rating Scale (C-SSRS) is an assessment tool to evaluate suicidal ideation and behavior. Categories have binary responses (yes/no) and include: Wish to be Dead; Non-specific Active Suicidal Thoughts; Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act; Active Suicidal Ideation with Some Intent to Act, without Specific Plan; Active Suicidal Ideation with Specific Plan and Intent, Preparatory Acts and Behavior; Aborted Attempt; Interrupted Attempt; Actual Attempt (non-fatal); Completed Suicide. Suicidal ideation or behavior is indicated by a "yes" answer to any of the listed categories. A score of 0 is assigned if no suicide risk is present. A score of 1 or higher indicates suicidal ideation or behavior. The SAF included all randomized participants who had received at least 1 dose of satralizumab or placebo.

End point type	Secondary
End point timeframe:	
Baseline and Post-Baseline (up to Week 224)	



End point values	Placebo + Baseline Treatment, then Satralizumab	Satralizumab + Baseline Treatment, then Satralizumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	41	41		
Units: participants				
Baseline (n=41, 40)	5	12		
Post-Baseline (n=41, 41)	2	3		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Blood Anti-Aquaporin-4 (AQP4) Antibody Concentration Over Time

End point title	Blood Anti-Aquaporin-4 (AQP4) Antibody Concentration Over Time
-----------------	--

End point description:

Drift in the anti-AQP4 antibody titer cell-based assay over time confounded longitudinal assessment of anti-AQP4 antibody titers and therefore these results cannot be reported.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Weeks 2, 4, 8, 12, 24, 48, and every 24 weeks thereafter of double-blind period; every 24 weeks for first 48 weeks of open-label extension period (up to approximately 7 years)

End point values	Placebo + Baseline Treatment, then Satralizumab	Satralizumab + Baseline Treatment, then Satralizumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	0 <sup>[2]</sup>	0 <sup>[3]</sup>		
Units: Units/mL				
arithmetic mean (standard deviation)	()	()		

Notes:

[2] - Longitudinal assessments of anti-AQP4 Ab titers were confounded and data are therefore not reported.

[3] - Longitudinal assessments of anti-AQP4 Ab titers were confounded and data are therefore not reported.

### Statistical analyses

No statistical analyses for this end point

### Secondary: Percentage of Blood Plasmablast Over Time

End point title	Percentage of Blood Plasmablast Over Time
-----------------	---

End point description:

The plasmablast assay lacked the sensitivity required to measure plasmablast levels at baseline in the majority of participants. Since most participants had plasmablast values below lower limit of quantitation (LLOQ) at baseline, longitudinal assessments could not be performed and therefore

plasmablast results are not reported.

End point type	Secondary
End point timeframe:	
Baseline, Weeks 2, 4, 8, 12, 24, 48 and every 24 weeks thereafter of double-blind period (up to approximately 30 months)	

End point values	Placebo + Baseline Treatment, then Satralizumab	Satralizumab + Baseline Treatment, then Satralizumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	0 <sup>[4]</sup>	0 <sup>[5]</sup>		
Units: percentage of plasmablasts				
arithmetic mean (standard deviation)	()	()		

Notes:

[4] - Due to lack of sensitivity of the plasmablast assay results are not reported.

[5] - Due to lack of sensitivity of the plasmablast assay results are not reported.

### Statistical analyses

No statistical analyses for this end point

### Secondary: Percentage of Participants with Anti-Drug Antibodies to Satralizumab in the DB Period

End point title	Percentage of Participants with Anti-Drug Antibodies to Satralizumab in the DB Period <sup>[6]</sup>
-----------------	--

End point description:

Reported here is the percentage of participants with at least one positive anti-drug antibody measurement during the DB period. The SAF included all randomized participants who had received at least 1 dose of satralizumab or placebo.

End point type	Secondary
----------------	-----------

End point timeframe:

Up to approximately Week 224

Notes:

[6] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint reports data only for the arm treated with satralizumab.

End point values	Satralizumab + Baseline Treatment, then Satralizumab			
Subject group type	Reporting group			
Number of subjects analysed	41			
Units: percentage				
number (not applicable)	41.5			

### Statistical analyses



## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Up to clinical cut-off date, 06 June 2018 (up to approximately 224 weeks).

Adverse event reporting additional description:

The SAF included all randomized participants who had received at least 1 dose of satralizumab or placebo.

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	16.1
--------------------	------

### Reporting groups

Reporting group title	Placebo + Baseline Treatment, DB Period
-----------------------	---

Reporting group description:

Participants received matching placebo, subcutaneous (SC) at Weeks 0, 2 and 4, and every 4 weeks (Q4W) thereafter throughout the double-blind (DB) period up to protocol-defined relapse or treated relapse in addition to baseline treatment.

Reporting group title	Placebo, then Satralizumab, OLE Period
-----------------------	--

Reporting group description:

Following placebo treatment in the DB period participants received satralizumab 120 mg SC injection (with or without baseline treatment) at Weeks 0, 2 and 4, and Q4W thereafter up to the clinical cut-off date (CCOD).

Reporting group title	Satralizumab, then Satralizumab, OLE Period
-----------------------	---

Reporting group description:

Following satralizumab treatment in the DB period participants received satralizumab 120 mg SC injection (with or without baseline treatment) at Weeks 0, 2 and 4, and Q4W thereafter up to the CCOD.

Reporting group title	Satralizumab + Baseline Treatment, DB Period
-----------------------	--

Reporting group description:

Participants received satralizumab 120 mg SC injection at Weeks 0, 2 and 4, and Q4W thereafter throughout the DB period up to protocol-defined relapse or treated relapse in addition to baseline treatment.

Serious adverse events	Placebo + Baseline Treatment, DB Period	Placebo, then Satralizumab, OLE Period	Satralizumab, then Satralizumab, OLE Period
Total subjects affected by serious adverse events			
subjects affected / exposed	9 / 42 (21.43%)	6 / 24 (25.00%)	5 / 18 (27.78%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Breast cancer			
subjects affected / exposed	1 / 42 (2.38%)	0 / 24 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatic cancer			

subjects affected / exposed	1 / 42 (2.38%)	0 / 24 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Injury, poisoning and procedural complications</b>			
Femur fracture			
subjects affected / exposed	0 / 42 (0.00%)	0 / 24 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal compression fracture			
subjects affected / exposed	0 / 42 (0.00%)	0 / 24 (0.00%)	1 / 18 (5.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper limb fracture			
subjects affected / exposed	0 / 42 (0.00%)	0 / 24 (0.00%)	1 / 18 (5.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Nervous system disorders</b>			
Convulsion			
subjects affected / exposed	0 / 42 (0.00%)	1 / 24 (4.17%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Parkinsonism			
subjects affected / exposed	0 / 42 (0.00%)	0 / 24 (0.00%)	1 / 18 (5.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tension headache			
subjects affected / exposed	0 / 42 (0.00%)	0 / 24 (0.00%)	1 / 18 (5.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Blood and lymphatic system disorders</b>			
Anaemia macrocytic			
subjects affected / exposed	0 / 42 (0.00%)	0 / 24 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Autoimmune thrombocytopenia			
subjects affected / exposed	1 / 42 (2.38%)	0 / 24 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Leukopenia			
subjects affected / exposed	1 / 42 (2.38%)	0 / 24 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lymphopenia			
subjects affected / exposed	1 / 42 (2.38%)	0 / 24 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Gait disturbance			
subjects affected / exposed	0 / 42 (0.00%)	0 / 24 (0.00%)	1 / 18 (5.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eye disorders			
Glaucoma			
subjects affected / exposed	0 / 42 (0.00%)	0 / 24 (0.00%)	1 / 18 (5.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Retinal vein thrombosis			
subjects affected / exposed	1 / 42 (2.38%)	0 / 24 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	1 / 42 (2.38%)	0 / 24 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reproductive system and breast disorders			
Cervical dysplasia			

subjects affected / exposed	0 / 42 (0.00%)	0 / 24 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Uterine polyp			
subjects affected / exposed	1 / 42 (2.38%)	0 / 24 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Suicide attempt			
subjects affected / exposed	0 / 42 (0.00%)	0 / 24 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Dysuria			
subjects affected / exposed	1 / 42 (2.38%)	1 / 24 (4.17%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Systemic lupus erythematosus			
subjects affected / exposed	0 / 42 (0.00%)	1 / 24 (4.17%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Appendicitis			
subjects affected / exposed	1 / 42 (2.38%)	1 / 24 (4.17%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	1 / 1	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cellulitis			
subjects affected / exposed	0 / 42 (0.00%)	1 / 24 (4.17%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endocarditis			

subjects affected / exposed	0 / 42 (0.00%)	1 / 24 (4.17%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Enterocolitis infectious			
subjects affected / exposed	0 / 42 (0.00%)	0 / 24 (0.00%)	1 / 18 (5.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Escherichia sepsis			
subjects affected / exposed	1 / 42 (2.38%)	0 / 24 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatitis E			
subjects affected / exposed	0 / 42 (0.00%)	0 / 24 (0.00%)	1 / 18 (5.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Influenza			
subjects affected / exposed	0 / 42 (0.00%)	0 / 24 (0.00%)	1 / 18 (5.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	0 / 42 (0.00%)	0 / 24 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection			
subjects affected / exposed	1 / 42 (2.38%)	0 / 24 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urosepsis			
subjects affected / exposed	0 / 42 (0.00%)	1 / 24 (4.17%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

<b>Serious adverse events</b>	Satralizumab + Baseline Treatment, DB Period		
-------------------------------	--	--	--



Total subjects affected by serious adverse events			
subjects affected / exposed	7 / 41 (17.07%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events	0		
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Breast cancer			
subjects affected / exposed	0 / 41 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hepatic cancer			
subjects affected / exposed	0 / 41 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Injury, poisoning and procedural complications			
Femur fracture			
subjects affected / exposed	1 / 41 (2.44%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Spinal compression fracture			
subjects affected / exposed	1 / 41 (2.44%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Upper limb fracture			
subjects affected / exposed	0 / 41 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Nervous system disorders			
Convulsion			
subjects affected / exposed	0 / 41 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Parkinsonism			

subjects affected / exposed	0 / 41 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Tension headache			
subjects affected / exposed	1 / 41 (2.44%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Blood and lymphatic system disorders			
Anaemia macrocytic			
subjects affected / exposed	1 / 41 (2.44%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Autoimmune thrombocytopenia			
subjects affected / exposed	0 / 41 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Leukopenia			
subjects affected / exposed	0 / 41 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Lymphopenia			
subjects affected / exposed	0 / 41 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
General disorders and administration site conditions			
Gait disturbance			
subjects affected / exposed	0 / 41 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Eye disorders			
Glaucoma			
subjects affected / exposed	0 / 41 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Retinal vein thrombosis			
subjects affected / exposed	0 / 41 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	0 / 41 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Reproductive system and breast disorders			
Cervical dysplasia			
subjects affected / exposed	1 / 41 (2.44%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Uterine polyp			
subjects affected / exposed	0 / 41 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Psychiatric disorders			
Suicide attempt			
subjects affected / exposed	1 / 41 (2.44%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Renal and urinary disorders			
Dysuria			
subjects affected / exposed	0 / 41 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Musculoskeletal and connective tissue disorders			
Systemic lupus erythematosus			
subjects affected / exposed	0 / 41 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Infections and infestations			

Appendicitis				
subjects affected / exposed	0 / 41 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Cellulitis				
subjects affected / exposed	0 / 41 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Endocarditis				
subjects affected / exposed	0 / 41 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Enterocolitis infectious				
subjects affected / exposed	0 / 41 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Escherichia sepsis				
subjects affected / exposed	0 / 41 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Hepatitis E				
subjects affected / exposed	0 / 41 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Influenza				
subjects affected / exposed	0 / 41 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pneumonia				
subjects affected / exposed	1 / 41 (2.44%)			
occurrences causally related to treatment / all	1 / 1			
deaths causally related to treatment / all	0 / 0			
Urinary tract infection				

subjects affected / exposed	1 / 41 (2.44%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Urosepsis			
subjects affected / exposed	0 / 41 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 5 %

<b>Non-serious adverse events</b>	Placebo + Baseline Treatment, DB Period	Placebo, then Satralizumab, OLE Period	Satralizumab, then Satralizumab, OLE Period
Total subjects affected by non-serious adverse events			
subjects affected / exposed	36 / 42 (85.71%)	23 / 24 (95.83%)	16 / 18 (88.89%)
Vascular disorders			
Flushing			
subjects affected / exposed	0 / 42 (0.00%)	2 / 24 (8.33%)	2 / 18 (11.11%)
occurrences (all)	0	2	2
Hypertension			
subjects affected / exposed	0 / 42 (0.00%)	1 / 24 (4.17%)	2 / 18 (11.11%)
occurrences (all)	0	2	4
Hypotension			
subjects affected / exposed	1 / 42 (2.38%)	2 / 24 (8.33%)	0 / 18 (0.00%)
occurrences (all)	1	2	0
General disorders and administration site conditions			
Fatigue			
subjects affected / exposed	1 / 42 (2.38%)	3 / 24 (12.50%)	1 / 18 (5.56%)
occurrences (all)	1	3	1
Pyrexia			
subjects affected / exposed	5 / 42 (11.90%)	1 / 24 (4.17%)	0 / 18 (0.00%)
occurrences (all)	7	1	0
Chest discomfort			
subjects affected / exposed	0 / 42 (0.00%)	0 / 24 (0.00%)	2 / 18 (11.11%)
occurrences (all)	0	0	2
Chills			

subjects affected / exposed	0 / 42 (0.00%)	0 / 24 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Feeling abnormal			
subjects affected / exposed	0 / 42 (0.00%)	0 / 24 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Feeling hot			
subjects affected / exposed	0 / 42 (0.00%)	0 / 24 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Malaise			
subjects affected / exposed	0 / 42 (0.00%)	0 / 24 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Non-cardiac chest pain			
subjects affected / exposed	0 / 42 (0.00%)	2 / 24 (8.33%)	0 / 18 (0.00%)
occurrences (all)	0	2	0
Oedema peripheral			
subjects affected / exposed	0 / 42 (0.00%)	0 / 24 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Reproductive system and breast disorders			
Amenorrhoea			
subjects affected / exposed	0 / 42 (0.00%)	0 / 24 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	2 / 42 (4.76%)	1 / 24 (4.17%)	1 / 18 (5.56%)
occurrences (all)	3	1	1
Oropharyngeal pain			
subjects affected / exposed	1 / 42 (2.38%)	2 / 24 (8.33%)	1 / 18 (5.56%)
occurrences (all)	1	2	1
Epistaxis			
subjects affected / exposed	0 / 42 (0.00%)	0 / 24 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Pharyngeal erythema			
subjects affected / exposed	0 / 42 (0.00%)	0 / 24 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Rhinorrhoea			

subjects affected / exposed	1 / 42 (2.38%)	0 / 24 (0.00%)	1 / 18 (5.56%)
occurrences (all)	1	0	2
Upper respiratory tract inflammation			
subjects affected / exposed	0 / 42 (0.00%)	1 / 24 (4.17%)	1 / 18 (5.56%)
occurrences (all)	0	1	1
Psychiatric disorders			
Anxiety			
subjects affected / exposed	1 / 42 (2.38%)	1 / 24 (4.17%)	2 / 18 (11.11%)
occurrences (all)	1	1	3
Depression			
subjects affected / exposed	1 / 42 (2.38%)	0 / 24 (0.00%)	1 / 18 (5.56%)
occurrences (all)	1	0	1
Insomnia			
subjects affected / exposed	0 / 42 (0.00%)	2 / 24 (8.33%)	2 / 18 (11.11%)
occurrences (all)	0	2	2
Panic disorder			
subjects affected / exposed	0 / 42 (0.00%)	0 / 24 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Investigations			
Aspartate aminotransferase increased			
subjects affected / exposed	3 / 42 (7.14%)	2 / 24 (8.33%)	1 / 18 (5.56%)
occurrences (all)	4	3	1
Lymphocyte count decreased			
subjects affected / exposed	2 / 42 (4.76%)	2 / 24 (8.33%)	1 / 18 (5.56%)
occurrences (all)	2	2	1
Serum ferritin decreased			
subjects affected / exposed	3 / 42 (7.14%)	1 / 24 (4.17%)	1 / 18 (5.56%)
occurrences (all)	3	1	1
Alanine aminotransferase increased			
subjects affected / exposed	2 / 42 (4.76%)	2 / 24 (8.33%)	1 / 18 (5.56%)
occurrences (all)	2	2	1
Blood alkaline phosphatase increased			
subjects affected / exposed	0 / 42 (0.00%)	0 / 24 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Blood creatine phosphokinase increased			

subjects affected / exposed	2 / 42 (4.76%)	1 / 24 (4.17%)	2 / 18 (11.11%)
occurrences (all)	3	1	2
Blood fibrinogen decreased			
subjects affected / exposed	0 / 42 (0.00%)	0 / 24 (0.00%)	2 / 18 (11.11%)
occurrences (all)	0	0	2
Blood fibrinogen increased			
subjects affected / exposed	1 / 42 (2.38%)	1 / 24 (4.17%)	1 / 18 (5.56%)
occurrences (all)	1	1	1
Blood pressure increased			
subjects affected / exposed	0 / 42 (0.00%)	0 / 24 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Blood urine			
subjects affected / exposed	0 / 42 (0.00%)	0 / 24 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Complement factor decreased			
subjects affected / exposed	0 / 42 (0.00%)	1 / 24 (4.17%)	2 / 18 (11.11%)
occurrences (all)	0	1	2
Gamma-glutamyltransferase increased			
subjects affected / exposed	1 / 42 (2.38%)	2 / 24 (8.33%)	0 / 18 (0.00%)
occurrences (all)	1	2	0
Low density lipoprotein increased			
subjects affected / exposed	0 / 42 (0.00%)	0 / 24 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Neutrophil count decreased			
subjects affected / exposed	0 / 42 (0.00%)	2 / 24 (8.33%)	0 / 18 (0.00%)
occurrences (all)	0	2	0
Platelet count decreased			
subjects affected / exposed	0 / 42 (0.00%)	0 / 24 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Protein urine present			
subjects affected / exposed	0 / 42 (0.00%)	0 / 24 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Prothrombin time prolonged			
subjects affected / exposed	0 / 42 (0.00%)	0 / 24 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1



Urobilinogen urine increased subjects affected / exposed occurrences (all)	0 / 42 (0.00%) 0	0 / 24 (0.00%) 0	1 / 18 (5.56%) 1
Weight decreased subjects affected / exposed occurrences (all)	1 / 42 (2.38%) 1	1 / 24 (4.17%) 1	1 / 18 (5.56%) 1
Weight increased subjects affected / exposed occurrences (all)	1 / 42 (2.38%) 1	1 / 24 (4.17%) 1	1 / 18 (5.56%) 1
White blood cell count decreased subjects affected / exposed occurrences (all)	0 / 42 (0.00%) 0	2 / 24 (8.33%) 2	0 / 18 (0.00%) 0
Injury, poisoning and procedural complications			
Fall subjects affected / exposed occurrences (all)	2 / 42 (4.76%) 2	1 / 24 (4.17%) 1	1 / 18 (5.56%) 1
Ligament sprain subjects affected / exposed occurrences (all)	1 / 42 (2.38%) 1	3 / 24 (12.50%) 3	0 / 18 (0.00%) 0
Thermal burn subjects affected / exposed occurrences (all)	2 / 42 (4.76%) 2	1 / 24 (4.17%) 1	2 / 18 (11.11%) 2
Arthropod sting subjects affected / exposed occurrences (all)	0 / 42 (0.00%) 0	0 / 24 (0.00%) 0	1 / 18 (5.56%) 1
Compression fracture subjects affected / exposed occurrences (all)	0 / 42 (0.00%) 0	0 / 24 (0.00%) 0	1 / 18 (5.56%) 1
Contusion subjects affected / exposed occurrences (all)	0 / 42 (0.00%) 0	0 / 24 (0.00%) 0	1 / 18 (5.56%) 1
Excoriation subjects affected / exposed occurrences (all)	0 / 42 (0.00%) 0	0 / 24 (0.00%) 0	1 / 18 (5.56%) 1
Joint injury			

subjects affected / exposed	1 / 42 (2.38%)	0 / 24 (0.00%)	1 / 18 (5.56%)
occurrences (all)	1	0	1
Lower limb fracture			
subjects affected / exposed	0 / 42 (0.00%)	0 / 24 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Pelvic fracture			
subjects affected / exposed	0 / 42 (0.00%)	0 / 24 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Wound			
subjects affected / exposed	1 / 42 (2.38%)	2 / 24 (8.33%)	1 / 18 (5.56%)
occurrences (all)	1	2	2
Congenital, familial and genetic disorders			
Left ventricle outflow tract obstruction			
subjects affected / exposed	0 / 42 (0.00%)	0 / 24 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Cardiac disorders			
Angina pectoris			
subjects affected / exposed	0 / 42 (0.00%)	0 / 24 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Bradycardia			
subjects affected / exposed	0 / 42 (0.00%)	1 / 24 (4.17%)	1 / 18 (5.56%)
occurrences (all)	0	1	1
Palpitations			
subjects affected / exposed	1 / 42 (2.38%)	2 / 24 (8.33%)	0 / 18 (0.00%)
occurrences (all)	2	3	0
Nervous system disorders			
Dizziness			
subjects affected / exposed	1 / 42 (2.38%)	3 / 24 (12.50%)	0 / 18 (0.00%)
occurrences (all)	1	3	0
Headache			
subjects affected / exposed	4 / 42 (9.52%)	4 / 24 (16.67%)	7 / 18 (38.89%)
occurrences (all)	6	5	11
Epilepsy			
subjects affected / exposed	0 / 42 (0.00%)	0 / 24 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Hypoaesthesia			

subjects affected / exposed	0 / 42 (0.00%)	0 / 24 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Intercostal neuralgia			
subjects affected / exposed	1 / 42 (2.38%)	0 / 24 (0.00%)	1 / 18 (5.56%)
occurrences (all)	1	0	1
Muscle spasticity			
subjects affected / exposed	1 / 42 (2.38%)	1 / 24 (4.17%)	1 / 18 (5.56%)
occurrences (all)	1	1	1
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	5 / 42 (11.90%)	3 / 24 (12.50%)	5 / 18 (27.78%)
occurrences (all)	8	3	6
Iron deficiency anaemia			
subjects affected / exposed	1 / 42 (2.38%)	1 / 24 (4.17%)	1 / 18 (5.56%)
occurrences (all)	1	1	1
Leukopenia			
subjects affected / exposed	4 / 42 (9.52%)	5 / 24 (20.83%)	3 / 18 (16.67%)
occurrences (all)	12	5	8
Lymphopenia			
subjects affected / exposed	4 / 42 (9.52%)	1 / 24 (4.17%)	3 / 18 (16.67%)
occurrences (all)	9	1	9
Neutropenia			
subjects affected / exposed	2 / 42 (4.76%)	1 / 24 (4.17%)	1 / 18 (5.56%)
occurrences (all)	3	1	2
Hypofibrinogenaemia			
subjects affected / exposed	0 / 42 (0.00%)	0 / 24 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Polycythaemia			
subjects affected / exposed	0 / 42 (0.00%)	0 / 24 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Ear and labyrinth disorders			
Vertigo			
subjects affected / exposed	1 / 42 (2.38%)	1 / 24 (4.17%)	2 / 18 (11.11%)
occurrences (all)	1	1	5
Eye disorders			

Conjunctival haemorrhage subjects affected / exposed occurrences (all)	0 / 42 (0.00%) 0	2 / 24 (8.33%) 4	2 / 18 (11.11%) 2
Blepharitis subjects affected / exposed occurrences (all)	0 / 42 (0.00%) 0	0 / 24 (0.00%) 0	1 / 18 (5.56%) 1
Blepharospasm subjects affected / exposed occurrences (all)	0 / 42 (0.00%) 0	0 / 24 (0.00%) 0	1 / 18 (5.56%) 1
Cataract subjects affected / exposed occurrences (all)	0 / 42 (0.00%) 0	1 / 24 (4.17%) 1	1 / 18 (5.56%) 1
Conjunctival deposit subjects affected / exposed occurrences (all)	0 / 42 (0.00%) 0	0 / 24 (0.00%) 0	1 / 18 (5.56%) 1
Conjunctivitis subjects affected / exposed occurrences (all)	0 / 42 (0.00%) 0	1 / 24 (4.17%) 1	2 / 18 (11.11%) 2
Dry eye subjects affected / exposed occurrences (all)	0 / 42 (0.00%) 0	1 / 24 (4.17%) 1	1 / 18 (5.56%) 1
Eye pruritus subjects affected / exposed occurrences (all)	0 / 42 (0.00%) 0	0 / 24 (0.00%) 0	1 / 18 (5.56%) 1
Glaucoma subjects affected / exposed occurrences (all)	0 / 42 (0.00%) 0	0 / 24 (0.00%) 0	1 / 18 (5.56%) 1
Retinal haemorrhage subjects affected / exposed occurrences (all)	0 / 42 (0.00%) 0	0 / 24 (0.00%) 0	1 / 18 (5.56%) 1
Gastrointestinal disorders Abdominal pain upper subjects affected / exposed occurrences (all)	1 / 42 (2.38%) 1	3 / 24 (12.50%) 3	0 / 18 (0.00%) 0
Constipation			

subjects affected / exposed	7 / 42 (16.67%)	4 / 24 (16.67%)	1 / 18 (5.56%)
occurrences (all)	8	7	2
Dental caries			
subjects affected / exposed	2 / 42 (4.76%)	4 / 24 (16.67%)	1 / 18 (5.56%)
occurrences (all)	2	5	1
Diarrhoea			
subjects affected / exposed	3 / 42 (7.14%)	2 / 24 (8.33%)	3 / 18 (16.67%)
occurrences (all)	3	2	4
Gastritis			
subjects affected / exposed	0 / 42 (0.00%)	2 / 24 (8.33%)	2 / 18 (11.11%)
occurrences (all)	0	2	2
Nausea			
subjects affected / exposed	3 / 42 (7.14%)	1 / 24 (4.17%)	2 / 18 (11.11%)
occurrences (all)	3	1	2
Toothache			
subjects affected / exposed	1 / 42 (2.38%)	4 / 24 (16.67%)	0 / 18 (0.00%)
occurrences (all)	1	5	0
Abdominal distension			
subjects affected / exposed	0 / 42 (0.00%)	0 / 24 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Abdominal pain			
subjects affected / exposed	0 / 42 (0.00%)	2 / 24 (8.33%)	0 / 18 (0.00%)
occurrences (all)	0	2	0
Dyspepsia			
subjects affected / exposed	0 / 42 (0.00%)	0 / 24 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Large intestine polyp			
subjects affected / exposed	0 / 42 (0.00%)	0 / 24 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Pancreatitis acute			
subjects affected / exposed	0 / 42 (0.00%)	0 / 24 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Plicated tongue			
subjects affected / exposed	0 / 42 (0.00%)	0 / 24 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Hepatobiliary disorders			

Hepatic function abnormal subjects affected / exposed occurrences (all)	1 / 42 (2.38%) 2	1 / 24 (4.17%) 2	1 / 18 (5.56%) 1
Hypertransaminasaemia subjects affected / exposed occurrences (all)	2 / 42 (4.76%) 2	0 / 24 (0.00%) 0	1 / 18 (5.56%) 2
Skin and subcutaneous tissue disorders			
Eczema subjects affected / exposed occurrences (all)	1 / 42 (2.38%) 1	3 / 24 (12.50%) 3	0 / 18 (0.00%) 0
Urticaria subjects affected / exposed occurrences (all)	0 / 42 (0.00%) 0	2 / 24 (8.33%) 2	0 / 18 (0.00%) 0
Acne subjects affected / exposed occurrences (all)	1 / 42 (2.38%) 1	1 / 24 (4.17%) 1	1 / 18 (5.56%) 1
Alopecia subjects affected / exposed occurrences (all)	0 / 42 (0.00%) 0	0 / 24 (0.00%) 0	2 / 18 (11.11%) 2
Erythema subjects affected / exposed occurrences (all)	1 / 42 (2.38%) 1	1 / 24 (4.17%) 1	1 / 18 (5.56%) 1
Rash subjects affected / exposed occurrences (all)	2 / 42 (4.76%) 2	1 / 24 (4.17%) 1	1 / 18 (5.56%) 3
Rash pruritic subjects affected / exposed occurrences (all)	0 / 42 (0.00%) 0	0 / 24 (0.00%) 0	1 / 18 (5.56%) 1
Renal and urinary disorders			
Leukocyturia subjects affected / exposed occurrences (all)	3 / 42 (7.14%) 3	2 / 24 (8.33%) 3	0 / 18 (0.00%) 0
Haematuria subjects affected / exposed occurrences (all)	2 / 42 (4.76%) 2	2 / 24 (8.33%) 2	0 / 18 (0.00%) 0
Nephrolithiasis			

subjects affected / exposed	0 / 42 (0.00%)	0 / 24 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	0 / 42 (0.00%)	1 / 24 (4.17%)	1 / 18 (5.56%)
occurrences (all)	0	1	1
Back pain			
subjects affected / exposed	5 / 42 (11.90%)	2 / 24 (8.33%)	3 / 18 (16.67%)
occurrences (all)	9	2	3
Myalgia			
subjects affected / exposed	2 / 42 (4.76%)	3 / 24 (12.50%)	1 / 18 (5.56%)
occurrences (all)	2	4	6
Pain in extremity			
subjects affected / exposed	3 / 42 (7.14%)	0 / 24 (0.00%)	0 / 18 (0.00%)
occurrences (all)	3	0	0
Intervertebral disc protrusion			
subjects affected / exposed	0 / 42 (0.00%)	0 / 24 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Muscle spasms			
subjects affected / exposed	0 / 42 (0.00%)	0 / 24 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Musculoskeletal stiffness			
subjects affected / exposed	0 / 42 (0.00%)	0 / 24 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Myopathy toxic			
subjects affected / exposed	1 / 42 (2.38%)	0 / 24 (0.00%)	1 / 18 (5.56%)
occurrences (all)	1	0	1
Neck pain			
subjects affected / exposed	0 / 42 (0.00%)	0 / 24 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Osteoarthritis			
subjects affected / exposed	0 / 42 (0.00%)	0 / 24 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Spinal osteoarthritis			

subjects affected / exposed	0 / 42 (0.00%)	0 / 24 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Spinal pain			
subjects affected / exposed	1 / 42 (2.38%)	0 / 24 (0.00%)	1 / 18 (5.56%)
occurrences (all)	1	0	1
Infections and infestations			
Cystitis			
subjects affected / exposed	4 / 42 (9.52%)	2 / 24 (8.33%)	4 / 18 (22.22%)
occurrences (all)	6	2	5
Herpes zoster			
subjects affected / exposed	1 / 42 (2.38%)	2 / 24 (8.33%)	0 / 18 (0.00%)
occurrences (all)	1	2	0
Influenza			
subjects affected / exposed	4 / 42 (9.52%)	2 / 24 (8.33%)	1 / 18 (5.56%)
occurrences (all)	5	3	1
Nasopharyngitis			
subjects affected / exposed	7 / 42 (16.67%)	10 / 24 (41.67%)	2 / 18 (11.11%)
occurrences (all)	13	35	5
Oral herpes			
subjects affected / exposed	3 / 42 (7.14%)	2 / 24 (8.33%)	1 / 18 (5.56%)
occurrences (all)	19	3	3
Pharyngitis			
subjects affected / exposed	3 / 42 (7.14%)	0 / 24 (0.00%)	1 / 18 (5.56%)
occurrences (all)	10	0	1
Rhinitis			
subjects affected / exposed	0 / 42 (0.00%)	0 / 24 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Sinusitis			
subjects affected / exposed	0 / 42 (0.00%)	2 / 24 (8.33%)	1 / 18 (5.56%)
occurrences (all)	0	2	1
Upper respiratory tract infection			
subjects affected / exposed	6 / 42 (14.29%)	6 / 24 (25.00%)	5 / 18 (27.78%)
occurrences (all)	11	7	18
Urinary tract infection			
subjects affected / exposed	7 / 42 (16.67%)	7 / 24 (29.17%)	2 / 18 (11.11%)
occurrences (all)	7	11	11



Bacteriuria			
subjects affected / exposed	1 / 42 (2.38%)	1 / 24 (4.17%)	1 / 18 (5.56%)
occurrences (all)	1	1	1
Cellulitis			
subjects affected / exposed	0 / 42 (0.00%)	0 / 24 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Hordeolum			
subjects affected / exposed	0 / 42 (0.00%)	2 / 24 (8.33%)	0 / 18 (0.00%)
occurrences (all)	0	2	0
Onychomycosis			
subjects affected / exposed	0 / 42 (0.00%)	0 / 24 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Oral candidiasis			
subjects affected / exposed	0 / 42 (0.00%)	0 / 24 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Otitis externa			
subjects affected / exposed	0 / 42 (0.00%)	2 / 24 (8.33%)	0 / 18 (0.00%)
occurrences (all)	0	2	0
Periodontitis			
subjects affected / exposed	0 / 42 (0.00%)	2 / 24 (8.33%)	1 / 18 (5.56%)
occurrences (all)	0	5	1
Pneumonia			
subjects affected / exposed	0 / 42 (0.00%)	0 / 24 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Pyelonephritis			
subjects affected / exposed	0 / 42 (0.00%)	0 / 24 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Respiratory tract infection			
subjects affected / exposed	1 / 42 (2.38%)	1 / 24 (4.17%)	1 / 18 (5.56%)
occurrences (all)	2	3	1
Viral upper respiratory tract infection			
subjects affected / exposed	2 / 42 (4.76%)	0 / 24 (0.00%)	1 / 18 (5.56%)
occurrences (all)	2	0	1
Metabolism and nutrition disorders			
Dyslipidaemia			

subjects affected / exposed	1 / 42 (2.38%)	2 / 24 (8.33%)	0 / 18 (0.00%)
occurrences (all)	1	2	0
Hypercholesterolaemia			
subjects affected / exposed	5 / 42 (11.90%)	3 / 24 (12.50%)	1 / 18 (5.56%)
occurrences (all)	5	4	7
Hyperlipidaemia			
subjects affected / exposed	0 / 42 (0.00%)	0 / 24 (0.00%)	2 / 18 (11.11%)
occurrences (all)	0	0	2
Dehydration			
subjects affected / exposed	0 / 42 (0.00%)	0 / 24 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Hyperglycaemia			
subjects affected / exposed	2 / 42 (4.76%)	2 / 24 (8.33%)	0 / 18 (0.00%)
occurrences (all)	2	2	0
Iron deficiency			
subjects affected / exposed	0 / 42 (0.00%)	0 / 24 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1

<b>Non-serious adverse events</b>	Satralizumab + Baseline Treatment, DB Period		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	33 / 41 (80.49%)		
Vascular disorders			
Flushing			
subjects affected / exposed	1 / 41 (2.44%)		
occurrences (all)	1		
Hypertension			
subjects affected / exposed	3 / 41 (7.32%)		
occurrences (all)	4		
Hypotension			
subjects affected / exposed	0 / 41 (0.00%)		
occurrences (all)	0		
General disorders and administration site conditions			
Fatigue			
subjects affected / exposed	2 / 41 (4.88%)		
occurrences (all)	2		
Pyrexia			

subjects affected / exposed	0 / 41 (0.00%)		
occurrences (all)	0		
Chest discomfort			
subjects affected / exposed	2 / 41 (4.88%)		
occurrences (all)	2		
Chills			
subjects affected / exposed	1 / 41 (2.44%)		
occurrences (all)	1		
Feeling abnormal			
subjects affected / exposed	0 / 41 (0.00%)		
occurrences (all)	0		
Feeling hot			
subjects affected / exposed	1 / 41 (2.44%)		
occurrences (all)	1		
Malaise			
subjects affected / exposed	1 / 41 (2.44%)		
occurrences (all)	1		
Non-cardiac chest pain			
subjects affected / exposed	0 / 41 (0.00%)		
occurrences (all)	0		
Oedema peripheral			
subjects affected / exposed	1 / 41 (2.44%)		
occurrences (all)	1		
Reproductive system and breast disorders			
Amenorrhoea			
subjects affected / exposed	1 / 41 (2.44%)		
occurrences (all)	1		
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	1 / 41 (2.44%)		
occurrences (all)	1		
Oropharyngeal pain			
subjects affected / exposed	3 / 41 (7.32%)		
occurrences (all)	4		
Epistaxis			

subjects affected / exposed	2 / 41 (4.88%)		
occurrences (all)	2		
Pharyngeal erythema			
subjects affected / exposed	0 / 41 (0.00%)		
occurrences (all)	0		
Rhinorrhoea			
subjects affected / exposed	1 / 41 (2.44%)		
occurrences (all)	1		
Upper respiratory tract inflammation			
subjects affected / exposed	0 / 41 (0.00%)		
occurrences (all)	0		
Psychiatric disorders			
Anxiety			
subjects affected / exposed	2 / 41 (4.88%)		
occurrences (all)	2		
Depression			
subjects affected / exposed	1 / 41 (2.44%)		
occurrences (all)	1		
Insomnia			
subjects affected / exposed	1 / 41 (2.44%)		
occurrences (all)	1		
Panic disorder			
subjects affected / exposed	0 / 41 (0.00%)		
occurrences (all)	0		
Investigations			
Aspartate aminotransferase increased			
subjects affected / exposed	1 / 41 (2.44%)		
occurrences (all)	1		
Lymphocyte count decreased			
subjects affected / exposed	1 / 41 (2.44%)		
occurrences (all)	1		
Serum ferritin decreased			
subjects affected / exposed	1 / 41 (2.44%)		
occurrences (all)	2		
Alanine aminotransferase increased			

subjects affected / exposed	1 / 41 (2.44%)		
occurrences (all)	1		
Blood alkaline phosphatase increased			
subjects affected / exposed	1 / 41 (2.44%)		
occurrences (all)	1		
Blood creatine phosphokinase increased			
subjects affected / exposed	1 / 41 (2.44%)		
occurrences (all)	1		
Blood fibrinogen decreased			
subjects affected / exposed	0 / 41 (0.00%)		
occurrences (all)	0		
Blood fibrinogen increased			
subjects affected / exposed	0 / 41 (0.00%)		
occurrences (all)	0		
Blood pressure increased			
subjects affected / exposed	0 / 41 (0.00%)		
occurrences (all)	0		
Blood urine			
subjects affected / exposed	0 / 41 (0.00%)		
occurrences (all)	0		
Complement factor decreased			
subjects affected / exposed	0 / 41 (0.00%)		
occurrences (all)	0		
Gamma-glutamyltransferase increased			
subjects affected / exposed	0 / 41 (0.00%)		
occurrences (all)	0		
Low density lipoprotein increased			
subjects affected / exposed	2 / 41 (4.88%)		
occurrences (all)	2		
Neutrophil count decreased			
subjects affected / exposed	2 / 41 (4.88%)		
occurrences (all)	2		
Platelet count decreased			

subjects affected / exposed	0 / 41 (0.00%)		
occurrences (all)	0		
Protein urine present			
subjects affected / exposed	1 / 41 (2.44%)		
occurrences (all)	1		
Prothrombin time prolonged			
subjects affected / exposed	0 / 41 (0.00%)		
occurrences (all)	0		
Urobilinogen urine increased			
subjects affected / exposed	1 / 41 (2.44%)		
occurrences (all)	1		
Weight decreased			
subjects affected / exposed	1 / 41 (2.44%)		
occurrences (all)	1		
Weight increased			
subjects affected / exposed	1 / 41 (2.44%)		
occurrences (all)	1		
White blood cell count decreased			
subjects affected / exposed	1 / 41 (2.44%)		
occurrences (all)	1		
Injury, poisoning and procedural complications			
Fall			
subjects affected / exposed	0 / 41 (0.00%)		
occurrences (all)	0		
Ligament sprain			
subjects affected / exposed	1 / 41 (2.44%)		
occurrences (all)	1		
Thermal burn			
subjects affected / exposed	1 / 41 (2.44%)		
occurrences (all)	1		
Arthropod sting			
subjects affected / exposed	1 / 41 (2.44%)		
occurrences (all)	1		
Compression fracture			

subjects affected / exposed	2 / 41 (4.88%)		
occurrences (all)	2		
Contusion			
subjects affected / exposed	1 / 41 (2.44%)		
occurrences (all)	1		
Excoriation			
subjects affected / exposed	1 / 41 (2.44%)		
occurrences (all)	1		
Joint injury			
subjects affected / exposed	0 / 41 (0.00%)		
occurrences (all)	0		
Lower limb fracture			
subjects affected / exposed	1 / 41 (2.44%)		
occurrences (all)	1		
Pelvic fracture			
subjects affected / exposed	0 / 41 (0.00%)		
occurrences (all)	0		
Wound			
subjects affected / exposed	1 / 41 (2.44%)		
occurrences (all)	2		
Congenital, familial and genetic disorders			
Left ventricle outflow tract obstruction			
subjects affected / exposed	0 / 41 (0.00%)		
occurrences (all)	0		
Cardiac disorders			
Angina pectoris			
subjects affected / exposed	1 / 41 (2.44%)		
occurrences (all)	1		
Bradycardia			
subjects affected / exposed	1 / 41 (2.44%)		
occurrences (all)	1		
Palpitations			
subjects affected / exposed	0 / 41 (0.00%)		
occurrences (all)	0		
Nervous system disorders			

Dizziness			
subjects affected / exposed	2 / 41 (4.88%)		
occurrences (all)	3		
Headache			
subjects affected / exposed	10 / 41 (24.39%)		
occurrences (all)	28		
Epilepsy			
subjects affected / exposed	0 / 41 (0.00%)		
occurrences (all)	0		
Hypoaesthesia			
subjects affected / exposed	1 / 41 (2.44%)		
occurrences (all)	1		
Intercostal neuralgia			
subjects affected / exposed	1 / 41 (2.44%)		
occurrences (all)	1		
Muscle spasticity			
subjects affected / exposed	0 / 41 (0.00%)		
occurrences (all)	0		
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	3 / 41 (7.32%)		
occurrences (all)	3		
Iron deficiency anaemia			
subjects affected / exposed	2 / 41 (4.88%)		
occurrences (all)	3		
Leukopenia			
subjects affected / exposed	6 / 41 (14.63%)		
occurrences (all)	10		
Lymphopenia			
subjects affected / exposed	3 / 41 (7.32%)		
occurrences (all)	7		
Neutropenia			
subjects affected / exposed	2 / 41 (4.88%)		
occurrences (all)	3		
Hypofibrinogenaemia			



subjects affected / exposed	1 / 41 (2.44%)		
occurrences (all)	1		
Polycythaemia			
subjects affected / exposed	1 / 41 (2.44%)		
occurrences (all)	1		
Ear and labyrinth disorders			
Vertigo			
subjects affected / exposed	2 / 41 (4.88%)		
occurrences (all)	2		
Eye disorders			
Conjunctival haemorrhage			
subjects affected / exposed	1 / 41 (2.44%)		
occurrences (all)	1		
Blepharitis			
subjects affected / exposed	0 / 41 (0.00%)		
occurrences (all)	0		
Blepharospasm			
subjects affected / exposed	0 / 41 (0.00%)		
occurrences (all)	0		
Cataract			
subjects affected / exposed	1 / 41 (2.44%)		
occurrences (all)	1		
Conjunctival deposit			
subjects affected / exposed	0 / 41 (0.00%)		
occurrences (all)	0		
Conjunctivitis			
subjects affected / exposed	0 / 41 (0.00%)		
occurrences (all)	0		
Dry eye			
subjects affected / exposed	1 / 41 (2.44%)		
occurrences (all)	1		
Eye pruritus			
subjects affected / exposed	0 / 41 (0.00%)		
occurrences (all)	0		
Glaucoma			

subjects affected / exposed	0 / 41 (0.00%)		
occurrences (all)	0		
Retinal haemorrhage			
subjects affected / exposed	1 / 41 (2.44%)		
occurrences (all)	1		
Gastrointestinal disorders			
Abdominal pain upper			
subjects affected / exposed	1 / 41 (2.44%)		
occurrences (all)	1		
Constipation			
subjects affected / exposed	2 / 41 (4.88%)		
occurrences (all)	2		
Dental caries			
subjects affected / exposed	2 / 41 (4.88%)		
occurrences (all)	2		
Diarrhoea			
subjects affected / exposed	1 / 41 (2.44%)		
occurrences (all)	3		
Gastritis			
subjects affected / exposed	4 / 41 (9.76%)		
occurrences (all)	4		
Nausea			
subjects affected / exposed	3 / 41 (7.32%)		
occurrences (all)	3		
Toothache			
subjects affected / exposed	0 / 41 (0.00%)		
occurrences (all)	0		
Abdominal distension			
subjects affected / exposed	1 / 41 (2.44%)		
occurrences (all)	1		
Abdominal pain			
subjects affected / exposed	2 / 41 (4.88%)		
occurrences (all)	2		
Dyspepsia			
subjects affected / exposed	1 / 41 (2.44%)		
occurrences (all)	1		

Large intestine polyp subjects affected / exposed occurrences (all)	1 / 41 (2.44%) 1		
Pancreatitis acute subjects affected / exposed occurrences (all)	0 / 41 (0.00%) 0		
Plicated tongue subjects affected / exposed occurrences (all)	1 / 41 (2.44%) 1		
Hepatobiliary disorders Hepatic function abnormal subjects affected / exposed occurrences (all)	0 / 41 (0.00%) 0		
Hypertransaminasaemia subjects affected / exposed occurrences (all)	1 / 41 (2.44%) 2		
Skin and subcutaneous tissue disorders Eczema subjects affected / exposed occurrences (all)	2 / 41 (4.88%) 2		
Urticaria subjects affected / exposed occurrences (all)	3 / 41 (7.32%) 3		
Acne subjects affected / exposed occurrences (all)	1 / 41 (2.44%) 1		
Alopecia subjects affected / exposed occurrences (all)	1 / 41 (2.44%) 1		
Erythema subjects affected / exposed occurrences (all)	1 / 41 (2.44%) 1		
Rash subjects affected / exposed occurrences (all)	0 / 41 (0.00%) 0		
Rash pruritic			

subjects affected / exposed	1 / 41 (2.44%)		
occurrences (all)	1		
Renal and urinary disorders			
Leukocyturia			
subjects affected / exposed	2 / 41 (4.88%)		
occurrences (all)	2		
Haematuria			
subjects affected / exposed	0 / 41 (0.00%)		
occurrences (all)	0		
Nephrolithiasis			
subjects affected / exposed	0 / 41 (0.00%)		
occurrences (all)	0		
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	4 / 41 (9.76%)		
occurrences (all)	4		
Back pain			
subjects affected / exposed	4 / 41 (9.76%)		
occurrences (all)	4		
Myalgia			
subjects affected / exposed	1 / 41 (2.44%)		
occurrences (all)	5		
Pain in extremity			
subjects affected / exposed	1 / 41 (2.44%)		
occurrences (all)	1		
Intervertebral disc protrusion			
subjects affected / exposed	0 / 41 (0.00%)		
occurrences (all)	0		
Muscle spasms			
subjects affected / exposed	0 / 41 (0.00%)		
occurrences (all)	0		
Musculoskeletal stiffness			
subjects affected / exposed	1 / 41 (2.44%)		
occurrences (all)	1		
Myopathy toxic			

subjects affected / exposed	1 / 41 (2.44%)		
occurrences (all)	1		
Neck pain			
subjects affected / exposed	1 / 41 (2.44%)		
occurrences (all)	1		
Osteoarthritis			
subjects affected / exposed	1 / 41 (2.44%)		
occurrences (all)	1		
Spinal osteoarthritis			
subjects affected / exposed	1 / 41 (2.44%)		
occurrences (all)	1		
Spinal pain			
subjects affected / exposed	2 / 41 (4.88%)		
occurrences (all)	2		
Infections and infestations			
Cystitis			
subjects affected / exposed	3 / 41 (7.32%)		
occurrences (all)	4		
Herpes zoster			
subjects affected / exposed	2 / 41 (4.88%)		
occurrences (all)	2		
Influenza			
subjects affected / exposed	0 / 41 (0.00%)		
occurrences (all)	0		
Nasopharyngitis			
subjects affected / exposed	10 / 41 (24.39%)		
occurrences (all)	22		
Oral herpes			
subjects affected / exposed	2 / 41 (4.88%)		
occurrences (all)	6		
Pharyngitis			
subjects affected / exposed	4 / 41 (9.76%)		
occurrences (all)	6		
Rhinitis			
subjects affected / exposed	3 / 41 (7.32%)		
occurrences (all)	4		

Sinusitis			
subjects affected / exposed	3 / 41 (7.32%)		
occurrences (all)	4		
Upper respiratory tract infection			
subjects affected / exposed	10 / 41 (24.39%)		
occurrences (all)	26		
Urinary tract infection			
subjects affected / exposed	6 / 41 (14.63%)		
occurrences (all)	8		
Bacteriuria			
subjects affected / exposed	0 / 41 (0.00%)		
occurrences (all)	0		
Cellulitis			
subjects affected / exposed	0 / 41 (0.00%)		
occurrences (all)	0		
Hordeolum			
subjects affected / exposed	0 / 41 (0.00%)		
occurrences (all)	0		
Onychomycosis			
subjects affected / exposed	1 / 41 (2.44%)		
occurrences (all)	1		
Oral candidiasis			
subjects affected / exposed	0 / 41 (0.00%)		
occurrences (all)	0		
Otitis externa			
subjects affected / exposed	0 / 41 (0.00%)		
occurrences (all)	0		
Periodontitis			
subjects affected / exposed	1 / 41 (2.44%)		
occurrences (all)	1		
Pneumonia			
subjects affected / exposed	0 / 41 (0.00%)		
occurrences (all)	0		
Pyelonephritis			
subjects affected / exposed	0 / 41 (0.00%)		
occurrences (all)	0		

Respiratory tract infection subjects affected / exposed occurrences (all)	0 / 41 (0.00%) 0		
Viral upper respiratory tract infection subjects affected / exposed occurrences (all)	1 / 41 (2.44%) 1		
Metabolism and nutrition disorders			
Dyslipidaemia subjects affected / exposed occurrences (all)	1 / 41 (2.44%) 1		
Hypercholesterolaemia subjects affected / exposed occurrences (all)	4 / 41 (9.76%) 10		
Hyperlipidaemia subjects affected / exposed occurrences (all)	2 / 41 (4.88%) 2		
Dehydration subjects affected / exposed occurrences (all)	0 / 41 (0.00%) 0		
Hyperglycaemia subjects affected / exposed occurrences (all)	0 / 41 (0.00%) 0		
Iron deficiency subjects affected / exposed occurrences (all)	2 / 41 (4.88%) 3		

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
29 November 2013	Definition of NMOSD was changed. The population was limited to optic neuritis or transverse myelitis with seropositivity in anti-AQP4 antibody. Adolescent subjects aged 12-17 years were allowed to enter the study. Considering the impact of previous treatment on safety and efficacy, the treatment prohibited duration was modified. Methods and duration of contraception were added to exclusion criteria. Because patients with NMO/NMOSD tend to show lower white blood cell value due to baseline treatment with immunosuppressant drugs, the white blood cell exclusion criterion was modified. The protocol v2 was released prior to any patients being enrolled in the study.
27 February 2014	Suicidality assessment (C-SSRS) was added as a safety objective per Food and Drug Administration (FDA) request. Based on epidemiologic data, the percentage of patients with negative anti-AQP4 serostatus at screening was capped at 30% in order to reflect the real world population. Further clarifications on the process of screening for potential clinical relapses were added. The roles and responsibilities of the treating and assessing investigator were introduced and the blinding of study and site personnel to certain laboratory parameters were clarified.
18 December 2014	The criteria for protocol-defined relapse (PDR) were aligned with another pivotal Phase III study in patients with NMO/NMOSD (study BN40900 / SA309JG/ EudraCT ID 2015-005431-41), which was modified based on FDA's comment. According to the Paediatric Committee's (PDCO's) request at least 8 adolescents were to be enrolled. Combination baseline treatment for adolescents was allowed given the low prevalence of pediatric patients and their treatment situation. Additional follow up assessments for adolescents were added. A blood sample collected before screening was accepted for anti-AQP4 antibody screening assessment in case the blood sample at screening was negative for anti-AQP4 antibody, considering the possibility that anti-AQP4 antibody status may change from positive to negative due to treatment for relapse. Permitted relapse treatments and prohibited treatments were modified considering clinical practice. Time limit of relapse evaluation to be recognized as PDR was aligned to another pivotal Phase III study in participants with NMO/NMOSD (study BN40900/SA-309JG// EudraCT ID 2015-005431-41) to avoid incomplete or biased reporting, and relapse assessment procedures were clarified. To avoid missing potential relapses, additional phone calls between visits and instructions to remind participants of possible relapse symptoms were added. The conditions when a participant could move from the double blind (DB) period to the open-label extension (OLE) period were clarified.
03 June 2015	Considering the clinical situation where no drugs have been approved for treatment of NMO and NMOSD, the open-label extension period was extended from an ethical point of view. This change was also in alignment with the agreed pediatric investigation plan (PIP). Inclusion of adolescents with negative anti-AQP4 serostatus at screening was allowed.
19 October 2015	Clarification that the population which was capped by anti-AQP4 antibody status at screening was limited only to adults.
14 December 2016	Addition that adolescents may be enrolled into the OLE period after the total number of PDRs confirmed by the clinical endpoint committee (CEC) reached 26. The minimum number of adolescents (12 to 17 years old) with positive anti-AQP4 serostatus at screening was changed from 6 to 4. The use of satralizumab prefilled syringe (PFS) with needle safety device (NSD) were implemented to be used in the OLE period after the total number of CEC confirmed PDRs reached 26.



17 April 2017	The description on the timing of satralizumab PFS with NSD implementation was modified so that satralizumab PFS with NSD could be administered for participants who had already entered into open-label extension period after availability at each study site. The reporting procedure when the medical device (satralizumab PFS with NSD) resulted in an adverse event (AE) to an individual other than the study participant was clarified.
---------------	--

Notes:

---

## **Interruptions (globally)**

Were there any global interruptions to the trial? No

## **Limitations and caveats**

None reported